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ABSTRACT
Clark, Reilly June, Ph. D., Biomedical Sciences, Wright State University. 2019. Differential
microRNA expression in Barrett’s Esophagus Correlates with Regulation of Posterior HOX
Genes.
Barrett’s Esophagus (BE) is characterized by the appearance of an intestinal-like epithelium in
the distal esophagus. The molecular mechanisms behind BE development are unknown. BE is
often preceded by Gastroesophageal Reflux Disease (GERD) and predisposes patients to
esophageal adenocarcinoma (EAC). Due to the high mortality rate associated with EAC, BE
patients are continuously monitored through upper endoscopy with biopsy for progression to low
grade dysplasia (LGD), high grade dysplasia, and EAC. This monitoring technique poses
numerous risks, so alternative surveillance and diagnostic techniques for BE pathogenesis are
continually studied. microRNA biomarkers in BE pathogenesis may provide alternative means of
diagnosis as well as a greater understanding of BE and its progression to EAC. Here, small RNAsequencing of serum and tissue from GERD, BE, LGD, and EAC patients revealed three
candidate tissue microRNAs differentially expressed in BE compared to GERD patients.
Differential expression of the three candidate microRNAs was validated in a second cohort of
BE and GERD patient tissues by quantitative PCR. Gene target analysis revealed two candidate
microRNAs are homeobox (HOX) microRNAs, which directly target central and posterior HOX
genes. HOX genes are transcription factors which regulate gene expression along the anterior/
posterior axis. BE resembles a homeotic transformation, which could be due to aberrant
expression of posterior HOX genes in the esophagus, an anterior organ. The third candidate
microRNA targets a component of Polycomb Repressive Complex 1, a transcriptional repressor
of HOX genes. Thus, the three candidate microRNAs may modulate posterior HOX gene
expression associated with BE development.
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INTRODUCTION
Barrett’s Esophagus (BE)
The esophagus serves as an intermediary organ in the human gastrointestinal system
between the oral cavity and the stomach. Unlike either of these organs, the esophagus
does not play a role in digestion or absorption of nutrients. In a normal human adult, the
entire esophagus is lined with a stratified squamous epithelium [1]. Several pathological
conditions of the esophagus exist including esophagitis, esophageal squamous cell
carcinoma, gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE), and
Esophageal Adenocarcinoma (EAC) [2, 3]. The three latter conditions are thought to be
linked.
GERD describes a chronic disorder in which gastric juice is refluxed past the lower
esophageal sphincter into the distal esophagus. GERD patients experience continual pain
and inflammation due to the chronic exposure of the esophageal epithelium to the acidic
refluxate [4, 5]. The incidence of GERD has been on the rise in the United States [6].
Obesity can be a precursor condition to GERD. Rising rates of adult obesity in the United
States are thought to be a contributing factor to GERD’s increased incidence [7].
However, the causes of GERD are varied and cannot always be linked to higher BMI [4].
Hiatal hernias and structural abnormalities in the esophageal sphincter are also associated
with this chronic disorder [8].
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In BE, regions of normal squamous epithelium are replaced by a simple columnar
epithelium interspersed with intestinal-type cells, termed intestinal metaplasia [9]. BE is
most associated with the presence of goblet cells in the distal esophagus, a typical cell
type in the small intestinal epithelium [10, 11]. A BE diagnosis is frequently preceded by
GERD [6, 12-14]. BE lesions do not present any additional symptoms, and there are no
treatments to reverse or prevent BE. The only recourse following a BE diagnosis are
antacids and proton pump inhibitors to increase the pH of the refluxate, mediating the
pain and inflammation characteristic of GERD [15]. Several studies have shown the
acidic environment created by gastric reflux can alter epithelial cell signaling [16, 17].
Introduction of bile acids from the small intestine through duodenal esophageal reflux
can promote intestinal-type gene expression in the esophageal epithelium, most notably
caudal-related homeobox 2 (CDX2) and acid mucin 2 (MUC2) [18]. It is still unclear
whether the intestinal-type signaling promoted by acid reflux is the initiating event of BE
development or a later event following replacement of the normal squamous epithelia.
A BE diagnosis does significantly increase patient risk for Esophageal Adenocarcinoma
(EAC). A risk evaluation by Cameron et al (1985) has shown that a BE patient’s risk for
EAC can reach 100 fold that of a patient without BE [19]. EAC diagnoses comprise less
than 1% of all cancer diagnoses every year in the United States [11, 20][11, 20][11,
20][11, 20]. Yet, EAC mortality rate has been reported as high as 80% [21]. EAC tumors
are difficult to diagnose in their early stages, as the epithelium of the distal esophagus is
impossible to self-monitor. Unless EAC is caught early enough to enable ablation or
surgical resection of the tumor, the five year survival rate is less than 5% [21]. Surgical
resection is the most successful treatment available for this cancer. Smoking and alcohol
2

consumption are minor risk factors for EAC, but the only known major risk factor for
EAC is BE [22]. EAC tumors have been shown to originate from BE lesions [23]. BE
pathogenesis follows a sequence: GERD, BE, BE with low grade dysplasia, BE with high
grade dysplasia, and finally EAC. Both the American Gastroenterological Association
(AGA) and the American College of Gastroenterology (ACG) recommend that GERD
and BE patients are monitored every 3-5 years for signs of BE lesions, dysplasia, and
EAC [10, 20]. Upon detection of dysplastic or cancerous tissue, the affected tissues are
either removed or subjected to more frequent monitoring. BE lesions without dysplastic
characteristics can remain benign for decades. It is estimated that only 0.2-2.1% of BE
patients progress to dysplasia or EAC every year [24]. Since it is not yet possible to
predict which BE patients will develop EAC, a BE diagnosis in a GERD patient does not
affect the AGA/ACG- recommended monitoring regimen.
Models for BE Development
Hypotheses abound concerning the origin of BE lesions [25]. Three major hypotheses
have been explored in the literature pertaining to BE development: transdifferentiation of
resident squamous epithelial stem cells, emergence of residual embryonic stem cells, and
migration of stem cells from a distinct location.
Transdifferentiation
In terms of the number of peer-reviewed studies, the “transdifferentiation” hypothesis for
BE development has been the most popular. This hypothesis posits that the squamous
epithelial stem cells of the distal esophagus transdifferentiate upon some stimulus into
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columnar epithelia cells to form BE lesions [26, 27]. In other tissues, it has been shown
that adult stem cells can transdifferentiate into other cell types [28, 29]. One study offers
an apparent intermediate stage in BE transdifferentiation, in which an epithelial cell had
markers of both squamous and columnar epithelia [30]. Alternately, Jiang et al (2017)
identified a transitional epithelium in the distal esophagus which contained a squamous–
columnar junction basal cell population [31]. Upon exposure to CDX2, these cells can
differentiate into intestinal-type cells. In the small intestine, columnar epithelia
transdifferentiate into goblet cells and other intestinal-type cells through the actions of
CDX1 and CDX2 [32]. CDX gene expression in the adult esophageal epithelium is a
well-validated marker of intestinal metaplasia [33-35]. In BE, CDX1 is known to
upregulate markers of epithelial differentiation, including cytokeratin 20 and villin [36].
Intestinal metaplasia in BE is positive for CDX2, MUC2, and villin expression [37].
CDX1 also targets effectors of Wnt, Retinoic Acid, and Fibroblast Growth Factor (FGF)
signaling [38-40]. CDX1 expression can induce transdifferentiation of esophageal
keratinocyte cell lines to a cell type which stains positive for acid mucins by Alcian Blue
staining [41]. It is therefore possible that CDX1 and CDX2 expression in BE results in
transdifferentiation of cells within an existing simple columnar epithelium to goblet cells
and other intestinal-type cells. However, the molecular signaling events that would lead
to squamous epithelial transdifferentiation have not been revealed.
Several studies have investigated the initiating factors which may prompt
transdifferentiation in BE, including bile acids and retinoic acid [18, 42, 43]. In a 2015
study by Sun et al, bile acid treatment in a rat model can induce expression of markers of
BE, including CDX2 and MUC2 in BE-like metaplastic lesions [42]. However, in that
4

study, the formation of the metaplasia was believed to result from the heightened
inflammatory response in the esophagus upon bile acid treatment. While it has been
shown that bile acids can be potent modulators of cell signaling, especially in a neutral
pH refluxate, no evidence has been put forth that shows its role in BE transdifferentiation.
In the embryonic esophagus, a simple columnar epithelium is differentiated into a
stratified squamous epithelium [44]. In embryogenesis, such differentiation of epithelial
stem cells is triggered by retinoic acid signaling [45]. Retinoic acid activity is increased
in BE lesions, which may elucidate the increased expression of CDX genes in those same
tissues [45]. CDX1 and CDX2 are downstream effectors of retinoic acid signaling [38,
46, 47]. Together, this indicates some role of retinoic acid signaling in BE development.
Residual embryonic cell populations
Tumor protein p63 is responsible for maintenance of stratified epithelia [48]. It has been
documented that BE tissues do not express p63, which distinguishes them from the
normal esophageal squamous epithelium [49]. In p63-null mice, stratified squamous
epithelial tissues are replaced by a simple columnar epithelium which resembles BE
lesions [48, 49]. Since p63 is not necessary for differentiation of the squamous
epithelium, a 2011 study by Wang et al contended that BE may not form from
transdifferentiation, but instead a physical replacement of the squamous cells by a
residual embryonic population of columnar epithelia [50]. In mouse embryonic
development of the esophagus and proximal stomach, a simple columnar epithelia
precedes the formation of the mature stratified squamous epithelium [51]. Also in the
Wang 2011 study, both human BE and the esophagus of a p63-null mouse were observed
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to exhibit similar expression of known BE biomarkers, including Keratins 8, 18, and 20,
as well as Anterior gradient 2 (Agr2), Trefoil factors (TFF) 1-3, and Villin1 [50, 52, 53].
CDX2, a marker of the intestinal-type cells which occur in BE lesions, is not expressed in
p63-null mouse esophagus [50]. Perhaps, expression of CDX2 expression in the distal
esophagus, and thus the appearance of intestinal-type cells, is a separate event from the
development of the simple columnar epithelium.
Stem Cell Migrations
The hypothesis that BE is the result of stem cell migration is also popular. The initial
location of the migrating stem cells is a matter of much debate. Since BE was first
described in the 1950s, there has been a number of studies investigating the idea that the
stem cells maintaining these lesions originate in the gastric cardia, the region of the
stomach immediately adjacent to the gastroesophageal junction[54-56]. The epithelium of
the gastric cardia is columnar, resembling the columnar epithelia characteristic of BE
[55]. Intestinal metaplasia does occur in the gastric cardia [57]. These lesions differ from
BE, as they do not possess the same drastically increased risk of cancer [58].
An alternate source for migrating BE stem cells are the esophageal submucosal glands.
Intestinal metaplasia has been discovered in these glands and is referred to colloquially as
buried metaplasia [59]. Some studies indicate that columnar epithelial cells are present in
these submucosal glands and even share mutations with adjacent BE lesions [60].
Surveillance through upper endoscopy with biopsy can miss the lesions [61]. Therefore, it
is currently unknown whether buried metaplasia is the source of BE lesions or simply an
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extension of adjacent lesions. Alternatively, Garman and McCall argue that buried
metaplasia may not be intestinal metaplasia but instead the result of acinar ductal
metaplasia [25].
Sarosi et al (2008) hypothesized and showed in a rat reflux model that bone marrow
derived cells found in the esophagus could be linked to formation of the intestinal
metaplasia [62]. This study was performed in a rat esophageal reflux model, and
formation of the intestinal metaplasia was observed after a bone marrow transplant. This
hypothesis remains controversial, because its applicability to human BE patients with
chronic acid reflux was not clearly established [17, 63].
While hypotheses concerning the cellular origin of BE abound in the literature, it has
become obvious that the inability to observe BE development in vivo, either in an animal
model or a 3-D human cell culture model has been a large roadblock in the field’s
progress [64]. Thus, the drive for insight into the origin of BE has turned towards the
differential signaling which occurs in each stage of BE pathogenesis [65]. Although each
hypothesis discussed regarding the origin of BE has merit, there is much to be learned
about these lesions. Our incomplete understanding of how BE develops and what induces
its progression to dysplasia and EAC hinders our ability to appropriately diagnosis, treat,
or prevent BE and EAC. Identifying pertinent signaling pathways and biomarkers for
each stage of BE pathogenesis may aid in these processes [66].
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Homeotic Genes in BE Development
BE lesions Resemble Homeotic Transformations
Homeotic transformation refers to the development of structures in an inappropriate body
region. The classic example occurs in Drosophila where a leg develops in the place of an
antennae, a phenomenon known as antennapedia [67]. Several human gene disorders are
attributed to homeotic transformations [68]. BE occurs in the esophagus, but it is
characterized by the appearance of an epithelium resembling a more posterior portion of
the gastrointestinal tract, the small intestine. BE developments in adulthood, rather than
during embryonic development, but its resemblance to homeotic transformations is
striking [9, 69]. Homeotic transformations are the result of dysregulated homeotic gene
expression [70].
Homeotic genes are transcription factors which contain a homeobox domain and
determine segment identity along the anterior/posterior axis. The ANTP class, the largest
class of homeotic genes, is only found in metazoans [71]. The name of this class is
derived from Antennapedia gene in Drosophila. 255 ANTP-class homeotic genes are
present in the human genome. Many of these are in the HOX, ParaHOX, and Nyx gene
clusters. Eight of the known human homeotic genes have been shown to be differentially
regulated in BE tissues (Table 1). The HOX and ParaHOX gene clusters are heavily
involved in the normal development of the human GI tract. These gene clusters are
hypothesized to have originated from the same ancestral ProtoHOX gene clusters, based
on the similarities in their homeobox domains [72].
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Table 1: Human ANTP-class Homeotic Genes Differentially Regulated or Mutated in BE
Pathogenesis
Gene
Symbol

Gene Name

Regulation/Mutation in BE

Reference

CDX1

caudal type homeobox 1

Upregulated

[1]

CDX2

caudal type homeobox 2

Upregulated

[2-5]

HOXB5

homeobox B5

Upregulated

[6]

HOXB6

homeobox B6

Upregulated

[6]

HOXB7

homeobox B7

Upregulated

[6, 7]

PDX1

pancreatic and duodenal

Upregulated

[8-10]

SNP1

[10-14]

homeobox 1
BARX1
MSX1
1

BARX homeobox 1
msh homeobox 1

SNP

SNP: single nucleotide polymorphism

9

1

[15]

HOX genes regulate Positional Expression of Intestinal-type Genes
Members of the HOX gene clusters are expressed throughout the body [72]. In
embryogenesis, HOX genes are expressed in the mesoderm in a certain pattern which
specifies each body segment, termed the HOX code [73]. As embryonic development
progresses, HOX gene expression is initiated in the posterior regions of the body and
spreads anteriorly [74]. This promotes “posterior prevalence” which endures past
embryonic development and into adulthood. HOX genes are essential in the formation
and specification of the three GI segments, the foregut, midgut, and hindgut, in
embryonic development [75-77].
In bilateral metazoans, HOX gene spatial and temporal expression along the AP axis is
essential in maintaining segmental identities [78]. As a result of genome duplications in
human evolution, HOX genes occur in four clusters: HOXA, HOXB, HOXC, and HOXD
[79, 80]. The expression of HOX genes in a cluster is collinear: the order of a HOX gene
on the chromosome determines its positional expression in the body. Posterior HOX
genes from the HOXB cluster have been shown to be upregulated in BE tissues (Table 1)
[69].
HOX genes are regulated by protein complexes which modify chromatin structure.
Polycomb Repressive Complexes (PRC) promote closed chromatin structure and repress
HOX gene expression, while Multiple Lineage Leukemia (MLL) complexes promote
open chromatin structure and activate HOX gene expression [81-84]. It is unknown how
these complexes are recruited to the appropriate HOX genes to regulate gene patterning
along the AP axis.
10

ParaHOX genes regulate posterior gut development as well as HOX gene expression
The ParaHOX gene cluster includes PDX1, CDX1, CDX2 and CDX4 [72]. Expression of
the ParaHOX genes are confined to the endoderm and regulate the expression of other
homeotic genes in the gut along the AP axis [72]. CDX2 is the most posterior ParaHOX
gene. All three CDX genes are expressed in the gut endoderm of the human embryo and
have roles in gene expression patterning in posterior segments of the gut [85]. Together,
these genes act as transcriptional activators for more than 3,000 genes [86]. They are
significant players in the maturation, differentiation, and maintenance of the intestinal
epithelium [86]. Both CDX1 and CDX2 are not expressed in the normal squamous
epithelium of the distal esophagus, yet aberrant expression of both CDX genes has been
widely documented in BE [17, 33-36, 87-89].
In a CDX2-null mouse embryo, an apparent homeotic transformation occurs, wherein the
intestine develops with a mucosa resembling the esophagus and proximal stomach
instead of the mature differentiated epithelium [87]. In BE, CDX1 is known to upregulate
markers of epithelial differentiation, including cytokeratin 20 and villin [90]. CDX1 also
targets effectors of Wnt, Retinoic Acid, and Fibroblast Growth Factor (FGF) signaling
[38-40]. CDX gene activity can be regulated by Wnt/B-catenin signaling and BMP4
signaling, which are dysregulated in BE [91].
In the small intestine, CDX1 and CDX2 regulate expression of the HOX genes [39].
Central genes from all four HOX gene clusters can be targeted directly by CDX2 [92].
HOXA genes have been found to be activated by CDX1. CDX1 binds to a CDX-binding
site in the HOXA gene cluster and acetylates Histone H3 at Lysine 27, an activating
11

epigenetic mark [93]. CDX gene inactivation can affect central HOX gene expression,
which can manifest as homeotic transformations in vertebral column [47].
Protein Markers of BE
BE tissue can be differentiated from normal esophageal tissue due to the presence of
intestinal-type cells and associated molecular signaling. Numerous signaling pathways
involved in inflammation, epithelial differentiation, and tumorigenesis are dysregulated
in BE lesions [94]. Sonic Hedgehog, canonical Notch, and NF-κB signaling all appear to
be dysregulated in BE tissues [95-99]. Intestinal-type proteins including various
columnar cytokeratins, AGR2, TFF1-3, villin, the acid mucins, and CDX1 and CDX2 are
aberrantly expressed in BE [37].
Epithelial cytokeratins are the intermediate filaments types I and II composing the
cytoskeleton of epithelial cells [100, 101]. Different subsets of cytokeratins (CK) are
expressed by normal squamous epithelium and BE lesions [102]. The diversity of
cytokeratin expression in epithelial tissues is thought to be linked not only to the
epithelial cell type but also to the extent of differentiation in the tissue [100, 103].
Squamous epithelia express a larger subset including CK10, CK13m and CK14 [36, 51].
Since BE lesions are a heterogeneous collection of different cells, the subset of
cytokeratins expressed can vary. CK7, CK8, CK18, CK19, and CK20 are all associated
with BE tissues [36, 51, 102]. Cytokeratins are known to be differentially expressed in
tumorigenic tissues and have been considered for serum biomarkers for various cancers
[100].
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Anterior gradient 2 (AGR2), Villin, and Trefoil Factors 1-3 (TFF1-3) are all proteins
expressed in mucosal epithelium, such as the lining of the small intestine [65]. Like the
columnar cytokeratins, villin is a cytoskeletal protein essential to form microvilli in the
small intestine [104]. The trefoil factors are associated with mucins secreted by columnar
epithelial and goblet cells in the small intestine [105]. All three proteins are highly
upregulated in BE and EAC [104-107].
The acid mucin, MUC2, is an excellent protein marker of BE lesions. Goblet cells, whose
presence is required to diagnose BE, and other intestinal-type cells secrete mucins,
including MUC2 [108]. Mucins are not normally expressed in the esophageal epithelium;
however, their expression in BE lesions results in an adherent mucous barrier [109]. This
barrier contains neutral mucins, acid mucins, sialomucins, and sulfomucins [110, 111].
The extent of expression and the types of mucins expressed vary among BE patients. The
expression of mucins is promoted by the abnormal expression of CDX2 in BE [89].
Surveillance of BE Development and Progression to EAC
Upper GI Endoscopy with Biopsy
The gold standard for surveillance of BE pathogenesis is an upper gastrointestinal
endoscopy with histological confirmation from biopsies [112, 113]. This invasive method
to diagnose and monitor BE first requires visual examination of the distal esophagus. BE
lesions possess a distinct color and texture compared to the normal esophageal
epithelium. Upon locating BE lesions, puncture biopsies are obtained along the length of
the lesion. In the standard Seattle protocol, biopsies are to be taken every 2 centimeters

13

[64]. The biopsies are examined for characteristics of BE as well as signs of dysplasia
and cancer. A hematoxylin-eosin stain shows the presence of the simple columnar
epithelium characteristic of BE, as well as signs of cancerous cells. Confirmation of BE is
done through Period-Acid Schiff (PAS) staining combined with an Alcian Blue stain
[58]. PAS stains neutral mucins, while Alcian Blue stains acid mucins. Acid mucins are
secreted by goblet cells, the defining characteristic of BE lesions [114, 115]. Neutral
mucins tend to be associated with the columnar epithelia [114]. While upper endoscopy
with biopsy is the most effective tool available to monitor patients for BE pathogenesis, it
poses risks to patients. Insertion of the endoscope into the esophagus can result in
coughing and gagging [116]. The need for sedation to prevent gagging to safely complete
the procedure is also a disadvantage to this method. Inflammation and esophageal tearing
can occur, as well as infection at the biopsy sites [117, 118]. Patient anxiety is extremely
common with these procedures and can prevent patient compliance to the suggested
surveillance regimen.
Dysplasia in BE lesions can be difficult to confirm histologically, as they rely on a
pathologist’s interpretation of a small number of biopsies. Montgomery et al (2001)
showed inflammation could obscure accurate diagnosis of a BE patient, even when the
tissue was examined by multiple experts [119]. This is a critical problem for patients and
clinicians. Early detection of dysplasia in BE patients is vital to diagnosing EAC in its
earliest stages, when it can be ablated or surgically resected from the esophagus. False
results from endoscopy with biopsy can lead to two undesirable scenarios. With a false
negative diagnosis, a patient progressing to metastatic EAC could have necessary
treatment delayed by months to years. In the case of a false positive diagnosis, a BE
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patient without dysplasia would face unnecessary additional surveillance with its
associated risks. The prevalence of false diagnoses in BE patients has been documented
[120, 121]. The invasiveness and health risks posed by upper endoscopy with biopsy
appear to far outweigh its sensitivity and specificity. The cost effectiveness of this
method has been controversial.
Alternative Surveillance Techniques
Producing an alternative surveillance technique for BE and its pathogenesis with superior
sensitivity, accuracy, and safety is a major clinical challenge. Several alternative
surveillance techniques to monitor BE pathogenesis exist but are not currently included in
AGA/ACG recommendations. These surveillance methods utilize visual examination of
the esophagus, epithelial cell collection, and biomarker analysis. A 2017 review by
Offman et al showed that many proposed alternative techniques explored rely on less
invasive visual examination of the esophagus but still require a puncture biopsy for a
confirmed BE diagnosis [116]. Cell collection methods such as the Cytosponge procedure
provide less invasive means to collect cells from the distal esophagus for diagnosis
confirmation [122]. Contamination by epithelia from the proximal esophagus and the oral
cavity is a concern for these alternate methods. A balloon-based cell collection method
described by Moinova et al (2018) circumvents this issue by protecting the sample inside
a capsule before withdrawal from the distal esophagus [123]. The invasiveness of the
original surveillance method is at least partially addressed by these alternatives. The
sensitivity and specificity of these techniques for BE pathogenesis still relies upon
histological analysis of the esophageal tissues or cells.
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Alternative Diagnostic Techniques
An alternative confirmation method is to probe for tissue biomarkers associated with each
stage of BE pathogenesis. BE tissues can be differentiated from normal squamous
epithelial tissues by the previously introduced protein markers of BE. However, it can be
difficult to distinguish non-dysplastic BE from BE with dysplasia, since many of the
same proteins are expressed yet the hallmarks of cancer observed in EAC are not present
[124, 125].
Epigenetic biomarkers can differentiate BE tissues from normal squamous epithelia.
Moinova et al found that DNA methylation at the vimentin and cyclin A1 loci could
differentiate BE patients from non-BE patients [123]. Prior to that study, Kaz et al (2016)
showed unique DNA methylation signatures between BE and EAC patients [126]. These
biomarkers are associated with the simple columnar epithelia in BE, rather than the
intestinal-type cells. The microRNAs are another set of promising epigenetic biomarkers
for BE pathogenesis. Over 90 microRNAs have been found to be differentially expressed
in BE and EAC when compared to normal squamous epithelia [94].
An ideal technique to diagnose BE pathogenesis would be serum biomarker testing.
Collection of patient blood is minimally invasive. Such testing requires a panel of serum
biomarkers which can differentiate among the stages of BE pathogenesis. Serum
metabolites can be used to differentiate BE from GERD and from BE with dysplasia
[127]. EAC can be identified by hypermethylation at the adenomatous polyposis coli
promoter regions [128]. In their exploratory study, Bus et al (2016) demonstrated that
seven serum microRNAs are differentially expressed in BE and EAC [129]. This was
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further supported by Chiam et al (2015) which identified serum microRNA signatures
which could distinguish BE patients from EAC patients [130].
Despite the potential protein, DNA methylation, and microRNA biomarkers for BE
pathogenesis, only the acid mucins are used as diagnostic biomarkers for BE in the clinic.
Upper endoscopy with biopsy remains the gold standard for diagnosis of BE and its
progression to EAC. One significant impediment to furthering these techniques is the
limited molecular understanding of BE development and its progression to EAC.
Utilizing microRNA Signatures to understand BE Pathogenesis
This study pursued biomarker signatures which could differentiate each stage of BE
pathogenesis. The biomarkers of interest here are the microRNAs. These noncoding
RNAs are between 11- 22 nucleotides in length and possess the ability to repress
translation [131]. Each microRNA contains a seed sequence that is complementary to a
region on its target genes’ transcripts. Usually, the mRNA target region is within the 3’
untranslated region (UTR) [132]. microRNAs bind as part of a RNA-induced silencing
complex (RISC) [133]. microRNAs repress translation through two mechanisms, either
by a physical block of ribosome binding or by recruitment of endonucleases [131] [134].
The RISC prevents ribosome binding to the target mRNA, leading to a reservoir
population of microRNA-associated ribonucleoprotein complexes [135]. Some mRNA
targets are then degraded, by removal of the poly A tail by GW182 and CCR4-NOT
deadenylase complexes [133]. Repression of translation by microRNA does not require
perfect complementarity between the seed sequence of the target. One microRNA can
target hundreds of gene transcripts across multiple signaling pathways, making them
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excellent indicators of disease [136-138]. MicroRNAs can also be introduced into the
bloodstream as part of exosomes. MicroRNAs have been identified as biomarkers for
colorectal cancer, breast cancer, diabetes mellitus, and traumatic brain injuries as well as
many other diseases and conditions [139-143].
Many serum and tissue microRNAs have been found to be differentially expressed in BE
and EAC [94]. None of these microRNAs are currently being used as a biomarker for BE,
and no study to date has systematically identified any microRNA serum or tissue
biomarkers for the development of BE. Despite the diverse roles microRNAs play in
molecular signaling, microRNA biomarkers have not been utilized to identify pertinent
signaling mechanisms in BE pathogenesis.
This study seeks to examine the relationship between microRNA expression and the
development and progression of BE. The first aim of this study was to identify a
microRNA signature which could differentiate among all stages of BE pathogenesis. No
such signature was identified. The second aim was to reveal microRNAs that were
differentially expressed in pair-wise comparisons between stages of BE pathogenesis.
Identified microRNAs appeared to be involved in EAC tumorigenesis or BE
development. The third and last aim of this study was to determine the biological
mechanisms and processes regulated by microRNAs differentially expressed in BE
pathogenesis. Certain microRNAs identified in this study have roles in the regulation of
posterior homeotic genes, which is consistent with the resemblance of BE to a homeotic
transformation.
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MATERIALS AND METHODS
Small RNA-sequencing of microRNAs in Patient Tissue and Serum Biopsies
Collection of Fresh-Frozen Tissue and Serum from Human Patients
Tissue and serum sample collection was performed at Dayton Veteran Administration
Hospital by Dr. Sangeeta Agrawal. Both tissue and serum samples were collected from
each patient during routine upper endoscopy with biopsy appointments. For this study, 76
tissue and serum samples were processed from 38 patients. Upon collection, fresh tissue
biopsies were kept in 100mL RNA-later at -80°C. Upon collection, serum biopsies were
kept in at -80°C until small RNA could be isolated.
The patients included were classified into five groups: GERD, BE, BE with indefinite
dysplasia, BE with low grade dysplasia and EAC. Patients were selected for this study
based on their initial diagnosis prior to collection of tissue and serum samples. For this
study, BE patients with indefinite dysplasia and BE patients with low grade dysplasia
were combined into one group termed LGD.
Tissue and serum samples from patients labelled Normal were also collected, yet this
group is not included in the final analysis. The Normal group was intended as a negative
control. However, after a preliminary analysis of the small RNA-seq data, it was
observed that microRNA expression in the Normal group was more variable than the
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other pathology groups in both serum and tissue. The Normal moniker only indicated the
absence of GERD or BE in these patients. It did not account for the variety of other
conditions which required the patient to undergo an upper GI endoscopy, thus they were
not healthy controls.
Prior to sequencing, small RNAs must be isolated from each sample and cDNA libraries
prepared from the isolated small RNAs. Under advisement from Life Technologies, the
manufacturer of the Ion Proton instrument, the patient tissue and serum samples were
prepared for sequencing in slightly differing manners. However, sequencing of tissue and
serum followed the same procedure.
Small RNA Isolation from Patient Tissue Samples
Small RNAs were isolated from homogenized tissues following the manufacturer’s
protocol provided for the mirVanaTM ParisTM RNA and Native Protein Purification kit
(#AM1556, ThermoFisher Scientific). Fresh-frozen tissues were removed from RNAlater and homogenized in 500mL Cell Disruption buffer. The tissue fragments were either
chopped into small pieces with a razor blade and then homogenized with a small handheld homogenizer or homogenized with a rotor-stator homogenizer. All tissue
homogenization was done on ice. Following small RNA isolation, the small RNAs were
treated with the TURBO DNA-freeTM kit (#AM1907, ThermoFisher Scientific) to
eliminate any possible DNA contamination. The lack of DNA contamination was
confirmed by monitoring the isolated product by quantitative polymerase chain reaction
(qPCR) for GAPDH amplification (#4333764T, Applied Biosystems).
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Yield and quality of the isolated small RNAs were assessed through the Agilent
Bioanalyzer small RNA kit (#5067-1548, Agilent Technologies). The Agilent
Bioanalyzer (#G2939BA, Agilent Technologies) acts as a digital agarose gel. The virtual
gel provides the percentage and concentration of microRNAs based on the size of
oligonucleotides in the isolation product. Isolation products which contained over 30%
microRNA were selected for sequencing and progressed to cDNA library preparation.
Small RNA Isolation from Patient Serum Samples
Although 1000μL serum is the recommended starting volume for small RNA isolation
from serum, 1000μL serum was not available for every patient in this study. In order to
limit introduction of variability into cDNA libraries made from the serum samples, the
starting volume was reduced to 600μL serum for every patient. Small RNAs were
isolated as directed by mirVanaTM ParisTM RNA and Native Protein Purification kit.
Yield and quality by Agilent Bioanalyzer small RNA chip was not assessed for serum
samples. Instead, the 20-30μL isolated product was concentrated to 5ul with a speed
vacuum concentrator.
cDNA Library Preparation of Tissue small RNAs
Tissue cDNA libraries were prepared using the Ion Total RNA-seq v2 kit by Ion
TorrentTM (#4479789, ThermoFisher Scientific). Per the kit protocol, the small RNA
yield is diluted to 10 μg/μl with nuclease-free water, based on the microRNA
concentration provided by the Agilent 2100 Bioanalyzer instrument. The small RNAs
were hybridized with a proprietary mix of adaptors which were ligated to the 5’ end of
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the small RNAs. The adaptors allow for the next steps which are reverse transcription to
cDNAs and subsequent amplification of the cDNAs. The proprietary PCR primers
require the presence of the hybridized adaptors in order to amplify the entire cDNA
population. The 3’ primer also includes a barcode sequence. These barcode primers allow
for patient samples to be differentiated from one another. This enables pooling of
multiple samples during sequencing and is essential later for data analysis. With the
inclusion of the adaptors and PCR primers, cDNAs reverse transcribed from microRNAs
tend to be between 94-114 nucleotides. To filter cDNA libraries for this size range, a
purification and size selection step was performed before and after cDNA amplification.
Since tissue samples contain a vast number of varied nucleic acids, the rigorous protocol
for the total RNA-seq v2 kit was utilized for purification and size selection, as it entails
two ethanol washes.
Following library preparation, the Agilent Bioanalyzer DNA 1000 chip (#5067-1504,
Agilent Technologies) was used to determine the quality of each cDNA library. The
DNA 1000 chip provides size ranges corresponding to small RNAs (50-300 base pairs)
and to microRNAs (94-114 base pairs). These size ranges account for the addition of
proprietary library primers and sequence adaptors to the cDNA libraries. Libraries with a
high percentage of microRNAs (> 30%) and a high concentration of small RNAs (< 100
nmol/l) underwent small RNA-sequencing.
cDNA Library Preparation of Serum small RNAs
Serum cDNA libraries were also prepared according to the Ion Total RNA-seq v2 kit
protocol, except for the purification and size-selection steps. The initial concentration of
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small RNA used for each serum cDNA library is unknown. However, the total volume
from small RNA isolation was concentrated to 5μl, and 4μl of that volume initiated
cDNA library preparation.
Since the concentration of total RNAs in serum is assumed to be lower than fresh-frozen
tissue, a less rigorous protocol for purification and size-selection is needed. Therefore,
the Total Exosome RNA and Protein Isolation kit (#4478545, ThermoFisher Scientific)
protocol was utilized for the purification and size-selection steps only.
As with the tissue samples, quality and quantity of cDNAs derived from small RNA and
microRNAs was assessed by the Agilent Bioanalyzer DNA 1000 chip.
Small RNA-sequencing of microRNAs in Patient Tissue and Serum Biopsies
In this study, the Ion ProtonTM system for Next-Generation Sequencing (Ion Torrent TM,
Life Technologies) was utilized to sequence small RNAs in each patient tissue and serum
sample.
Small RNA-sequencing requires pooling of samples and another amplification of the
cDNA libraries by emulsion PCR. First, each cDNA library was diluted to 5nM with
nuclease-free water, and then up to 14 samples were pooled together and diluted to a final
total cDNA library concentration. The Ion One TouchTM 2 system (#4474779, Life
Technologies) was utilized for emulsion PCR. In emulsion PCR, every cDNA library
fragment was ligated onto an Ion Sphere TM Particle (ISP) beads and then amplified (Ion
PITM Hi-QTM OT2 200 kit, #A26434, Life Technologies). The 3’ primer for emulsion
PCR contains a B primer sequence which can hybridize with the ISPs as well as the P1
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adaptor sequences. A quality control step was included at this stage using the Ion
SphereTM assay for the QubitTM 2.0 Fluorometer (#4468656, #Q32866, Invitrogen). The
quality control metric was the percentage of ISP beads which contained successfully
ligated cDNA library fragments, termed the Percent Templated ISPs. The minimum
percentage suggested by the manufacturer is 10%. This percentage is derived from the
fluorescence of two fluorescent probes, Alexa FluorTM 647 and Alexa FluorTM 488. Alexa
FluorTM 647 binds to the A adaptor sequences. Alexa FluorTM 488 anneals to a site on the
B primer sequence. For the Ion Proton system, less than 10% Templated ISPs could result
in a lower amount of total sequenced reads for a small RNA-seq run (Appendix I).
Ideally, each ISP was populated with only one cDNA library fragment. However, multitemplated ISPs do occur. In this study, the Percent Templated ISPs was not an ideal
indicator of their occurrence or the total reads sequenced in a small-RNA seq run
(Appendix I). Following the QubitTM assay, the ISPs were loaded onto an Ion PI
sequencing chip for small RNA-seq.
Small RNA-sequencing required the Ion PITM Hi-QTM Sequencing 200 kit (#A26772,
Life Technologies) and the Ion PITM Chip (#A26771, Life Technologies). The sequencing
results underwent a preliminary analysis in the small RNA_analysis plugin provided by
the Ion Torrent Suite v.5.10 software. The analysis plugin software provided the total
small RNA reads and microRNA reads per patient sample. Raw sequences for those
samples which yielded 200,000 or more microRNA reads were uploaded to Partek ®
Flow® (Partek Incorporated) to be converted to normalized microRNA read counts for
analysis.
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Preparing small RNA sequences for Analysis of Differential microRNA Expression
Raw small RNA sequences are not ready fodder for analysis of differential microRNA
expression, because the identity and quantity of microRNAs in each sample is not
available. Here, Partek® Flow® software (Partek Incorporated) was utilized to convert
the raw sequences (available in .fastQ format) into a more readily analyzed format:
normalized microRNA read counts. Small RNA sequences from the 21 tissue samples
were analyzed separately from the small RNA sequences for the 25 serum samples.
Pre-Alignment Processing Removes Low Quality Bases from Raw Sequences
Partek® Flow® allows for trimming of bases from the 5’end or 3’ end of sequenced reads,
in order to maximize the alignment of reads to a reference database. In the sequencing
process, both ends of a read are the result of more cycles than the middle portion, which
predisposes base calls at either end to be less reliable.
Standard practice is to trim sequences of bases with a Phred quality score below 20. A
Phred quality score describes the likelihood of a miscalled base. A Phred quality score of
20 is equivalent to a 1% probability of a miscalled base. To facilitate downstream
processes, read lengths of approximately 170 base pairs were required. In order to obtain
this read length for reads in all cDNA libraries, trimming was based on a Phred quality
score of 19 or a 1.26% probability of a miscalled base. Sequences derived from
microRNA products were between 94-114bp. Parameters for base trimming for the serum
and tissue datasets maintained a minimum read length of 15bp.
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Aligning the Raw Sequences to miRBase v.21 eliminates non-microRNA sequences from
Analysis
Following base trimming, the raw sequences were aligned to a genome reference. Since
our interest was solely in microRNA expression, the genome reference was miRBase
v.21, a database which has compiled the sequences of every known human microRNA
[144, 145]. In line with current literature and recommendations from Partek, the aligner
algorithm used was the Bowtie aligner [146, 147]. Bowtie was constructed specifically to
align short DNA sequences to larger genome references.
Quantification of aligned reads to miRBase v.21 results in microRNA read counts
In order to convert the raw sequences to microRNA read counts, the aligned sequences
must be quantified. Here, the sequences were mapped to known human microRNA
sequences using a microRNA annotation file from miRBase v.21. Partek ® Flow®’s
modified expectation/maximization (E/M) quantification algorithm provided estimated
expression for each microRNA. Partek® Flow® documentation indicates this modified
algorithm can also correct for any sequences which map to multiple locations in the
human genome. Here, minimum seed length was set to 10bp with only 1 mismatch
allowed between a read and a known microRNA seed sequence.
Normalization of microRNA read counts by Trimmed Mean of M-values
A Trimmed Mean of M-values (TMM) normalization was applied to the microRNA read
count datasets for the tissue and serum samples [148-150]. This is to account for the
variability in total microRNA reads in each patient sample, which can vary due to any of
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the many technical steps required for small RNA sequencing. TMM was advantageous,
because it does not use microRNAs with very low or very high expression for
normalization. The distribution of microRNA read counts in the serum and tissue datasets
was skewed to the right, due to the presence of those microRNAs with very high
expression. Instead, this method focuses only on the microRNAs for which the read
count distribution in all samples approximates a Normal distribution.
A portion of microRNAs had zero read counts in some tissue and serum samples,
therefore an offset value of 1.00 was added to each read count value to prevent non-zero
errors in the calculation of M-values in TMM normalization. This offset value also
prevents non-zero errors in the calculation of expression fold change in downstream
analyses.
Filtering based on TMM-normalized microRNA read count applied to Serum and Tissue
datasets
Both the serum and tissue datasets were filtered in Partek TM FlowTM for microRNAs
which contained 100 or more TMM-normalized microRNA read counts in 25% of patient
samples. All downstream analyses were performed on the filtered serum and tissue
datasets. This 100 microRNA read count filter was intended to reduce the absolute noise
caused by microRNAs with very low read counts in most samples in the datasets. In
addition, this threshold alleviates the possibility that significant differential expression is
due to sequencing anomalies [151].
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The minimum number of microRNA read counts permitted for each sequenced sample
included in data analysis was 200,000. After alignment and quantitation to miRbase v.21,
the minimum average read count for each microRNA in each sample was 77.28. Thus,
setting the microRNA count threshold to 100 microRNA read counts was not a
particularly stringent filter. This read count filter allowed for low read counts in one
pathology group, while retaining enough in the three other pathology groups to allow for
ready detection of any differential microRNA expression.
Identification of Potential microRNA Signatures from Normalized microRNA Read
Counts
Since only a total of 21-25 patients were included in the serum and tissue analyses, this
severely limits the statistical methods which can be utilized to analyze the filtered TMMnormalized microRNA read count data. To identify microRNA signatures which could
differentiate all the stages of BE pathogenesis, three general techniques were utilized:
clustering analyses, Nearest Shrunken Centroids (NSC) classification, and the
randomForest classifier.
Here, the clustering analyses used were hierarchical clustering and a combination of a
heat map analysis with k-means clustering. Both analyses were performed in the Orange
Data Mining version 3.20.1 software [152].
The R Statistical Programming software provides an interface for several statistical
packages useful for analyzing large data sets [153]. The randomForest package in R is an
excellent candidate to analyze the dataset in this study, as it allows for a large p and a
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comparatively small n [154, 155]. Since BE pathogenesis follows a defined step-wise
progression, classification randomForest and regression randomForest analyses were both
deemed appropriate for this study. The regression component allows the regression
randomForest to account for pathology order. For this analysis, the stages of BE
pathogenesis were numbered sequentially with GERD being 1 and EAC being 4. Nearest
Shrunken Centroids (NSC) analysis was performed using the pamr package in R [156].
Pair-wise Comparisons Between Pathology Groups to Identify Candidate
microRNAs
Candidate microRNAs in this study are those microRNAs which are differentially
expressed between two pathology groups. Identification and subsequent gene target
analysis of these microRNAs was utilized to understand BE pathogenesis.
The Partek® Flow® software contains a Gene Specific Analysis (GSA) function which
allows grouping of samples into categories and pair-wise comparisons between the
sample groups. Here, the patient samples were grouped by their pathology: GERD, BE,
LGD, and EAC. To execute the comparisons, the Log Normal with Shrinkage (LNS)
statistical model was selected as the best model for this study. The Akaike Information
Criterion corrected (AICc) values for each microRNA tended to be lowest when utilizing
the LNS model in our study and in a 2004 study by Burnham and Anderson [157]. The
AICc values are measures of how well a statistical model fits a data set [158, 159].
Partek ® Flow ® documentation regarding the use of LNS in the GSA suggests exclusion
of features in the datasets with very low expression. To accomplish this, the lowest
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average coverage value was increased from 1.0 to 4.0 in both the tissue and the serum
analyses. This value was based on a visual examination of the LNS shrinkage plot
generated in Partek ® Flow ®. This eliminated any microRNAs which had a geometric
mean across all samples below 4.0. The comparisons made were according to the
sequence followed by BE pathogenesis: BE vs GERD, LGD vs BE, EAC vs BE, and
EAC vs LGD. The GSA algorithm then provided an uncorrected p-value and fold change
for each microRNA in each sample.
Before application of GSA algorithm, the total number of microRNAs aligned and
quantified to miRBase v.21 was 2,588. After adjusting the lowest average coverage to
4.0, the number of tissue microRNAs reduces to 1,193, while the number of serum
microRNAs decreases to 718 microRNAs.
In order to identify candidate microRNA biomarkers from each comparison, a Bonferroni
threshold was applied to the p-values generated by the GSA [160, 161]. Here, 0.05 was
set as the desired ɑ value, and the number of observations was equal to the total number
of microRNAs.
Gene Target Analysis for Selected Candidate microRNA biomarkers
Two approaches exist to identify gene targets for a given microRNA from gene target
databases. The first requires the use of a proprietary algorithm which predicts gene
targets for a microRNA based on its seed sequence as well as other factors. Which factors
are included in the algorithm differ based on the target database. This first approach is
utilized by miRDB and TargetScan Human 7.2 (Table 2) [162-165]. The second approach
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Table 2: Gene Target Analysis Utilizes Four Distinct Methods
Method

Target Type

Filtering of Gene Target Results

Predicted

Target Prediction Score ≥ 80

TargetScan
Human 7.2

Predicted

Cumulative weighted context ++ score < 0

DIANA
TarBase v.8

Experimentally-validated

Validated by at ≥ 2 low-throughput
experiments

miRDB

miRNet

Predicted,

Validated by ≥ 1 luciferase reporter assay
experiments

Experimentally-validated
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is experimental microRNA target identification. This can be achieved through a variety
of high-throughput and low-throughput methods, including expression profiling
following microRNA inhibition or luciferase reporter assays. TarBase v.8 from the
DIANA toolbox provides a compilation of experimentally-validated gene targets for each
microRNA, while miRNet includes gene targets from multiple target databases utilizing
both approaches (Table 2) [166, 167].
Several reference databases exist which have compiled experimentally-validated gene
targets for many of the known human microRNAs. TarBase v8 and miRNet are two
reference databases utilized to uncover gene targets for the six candidate microRNAs
[166, 167]. Low-throughput assays are utilized for validation of microRNA gene targets,
which are often first identified by genome-wide high-throughput screening experiments.
Results from TarBase v8 were filtered for low-throughput assays only for this study
(Table 2). Luciferase reporter assays are considered one of the most reliable lowthroughput assays to validate microRNA gene targets [168, 169]. The gene targets
compiled by miRNet were filtered for those targets which were validated by luciferase
reporter assay (Table 2).
A gene’s expression can be indirectly affected by a microRNA. It is important to verify
that a potential gene target contains at least one 6-8mer target site for a microRNA.
Various algorithms have been created to predict microRNA targets based on microRNA
sequence and potential target gene sequences. Here, Target Scan 7.2 and miRDB are two
target prediction algorithms used to predict targets of the six candidate microRNAs
(Table 2) [162, 165]. miRDB generates a prediction rank for each gene target. According
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to the algorithm’s creators, a rank score above 80 is deemed acceptable [165]. Results
from miRDB are filtered for targets ranking 80 or above (Table 2).
Quantitative Real-Time PCR validation of Candidate microRNAs in Human Patient
Tissues
Another set of human patient tissues was obtained for validation of the small RNA-seq
experiments. This cohort included 26 formalin-fixed paraffin-embedded (FFPE) samples
from patients diagnosed with either Barrett’s Esophagus or Gastroesophageal Reflux
Disease. The n for these experiments was based on the normalized microRNA read
counts for the chosen candidate microRNAs obtained by small RNA-seq. 80% statistical
power was desired, thus a total of 13 samples was necessary for each of the two
pathology groups of interest.
Total RNA was extracted from the FFPE tissues using the Covaris truXTRAC FFPE
microtube RNA kit (Covaris, #520161). This method utilizes the Covaris Adaptive
Focused Acoustics technology to remove the paraffin from the tissues prior to total RNA
extraction. The protocol for the Covaris kit was followed with an additional wash with
the provided ethanol-based buffer. Without the additional wash, guanidine ITC
contamination was sometimes detected following elution off the Covaris-provided
columns. Quality and quantity of total RNA yield was assessed via a ThermoFisher
Nanodrop ONE spectrophotometer. The guanidine ITC contamination was indicated by a
low 260/230 absorbance ratio.
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cDNA synthesis and qPCR followed the protocol for the TaqMan Advanced microRNA
assays (#A25576, #A28007). 10ng total RNA proved to be adequate starting material.
The Applied Biosystems™ QuantStudio™ 7 Flex Real-Time PCR System was used to
perform qPCR on four experimental plates. To assess differential expression of candidate
microRNAs, the TaqMan® Advanced miRNA Assays for each candidate microRNA
were selected (478230_mir, 478585_mir, 478769_mir). The ΔΔ Ct method was used to
analyze the output of the qPCR experiments [170]. Since this is a relative quantitative
method, an endogenous control microRNA was needed to provide the ΔCt values.
Several endogenous control microRNAs are suggested by TaqMan®; however, there are
no microRNAs which are known to keep constant expression in distal esophageal tissues.
One of the suggested microRNAs, hsa-miR-423-5p (478090_mir) was chosen as the
endogenous control microRNA as it did not display significant differential expression
between the GERD and BE tissues in the small RNA-seq experiments.
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RESULTS
Small RNA-sequencing of microRNAs from Patient Serum and Fresh-Frozen Tissue
Construction of cDNA libraries for small RNA-sequencing
Thirty-eight patients were included in this study: 12 GERD, 9 BE, 6 LGD, 5 EAC, 5
Normal, and 1 Esophageal Squamous Cell Carcinoma (ESCC). The ESCC sample
initially had been identified as EAC. When it was accurately identified as ESCC it was
excluded from all further analyses. At least one serum and one fresh-frozen tissue biopsy
was collected from each patient at a routine upper endoscopy appointment. For small
RNA-sequencing of microRNAs, cDNA libraries were constructed from small RNAs
extracted from patient serum and fresh-frozen tissue. Total RNA was first extracted from
each patient sample through a phenol extraction followed by a solid-phase extraction on
glass-fiber filters. Small RNAs were enriched using a larger concentration of ethanol,
thereby increasing their binding affinity for a second filter before elution into 40ul
nuclease-free water.
In the samples extracted from fresh-frozen tissue, a DNase-treatment was applied to 30ul
extracted small RNA to eliminate any potential DNA contamination. Effectiveness of
DNase treatment was verified by lack of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) amplification via qPCR. Then total small RNA concentration and microRNA
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concentration were assessed by an Agilent 2100 Bioanalyzer (Figure 1). Generally small
RNA samples with over 30% microRNA were selected for cDNA library preparation
(Table 3). 10ng microRNA was utilized to construct cDNA libraries for the tissue
samples.
Small RNA samples extracted from patient serum were not treated with DNase or
assessed by Agilent 2100 Bioanalyzer. It was determined that DNase treatment could
detrimentally affect the already low yield of small RNA extraction from serum (Michael
Zianni, Thermo Fisher Scientific, Personal Communication). Preliminary experiments
with small RNA extraction from serum samples found that concentrations of small RNAs
extracted from the serum samples were often below the quantitative range of the Agilent
2100 Bioanalyzer (50-2000 pg/ul). This is not unprecedented, and in previous studies, a
fixed volume was utilized rather than a fixed microRNA concentration for cDNA library
construction [171]. The 30ul eluant from small RNA extraction was concentrated to 4ul
using a Savant DNA Speed Vac Concentrator.
For cDNA libraries constructed from either serum or tissue libraries, double stranded
DNA/RNA adaptors from the Ion Adaptor Mix v2 (Ion Total RNAseq kit v2) were
ligated to both ends of the small RNAs prior to reverse transcription (Figure 2). These
adaptors contain degenerate bases which allow for first strand synthesis. Size-selection
for desired RNA products was then implemented by another solid-phase extraction. Here,
the cDNA library fragments were bound to nucleic acid binding magnetic beads. For the
tissue samples, the protocol first bound larger RNA products, such as from mRNA and
rRNA, to the magnetic beads. Then the small RNA products were bound to beads with an
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Figure 1: Assessment of small RNA and microRNA Yields following small RNA
Extraction
A representative small RNA sample extracted from patient tissue biopsy (Agilent
Bioanalyzer small RNA chip). Peaks shown represent total small RNA from a 1
microliter aliquot. Peaks between 10-40 nucleotides were considered microRNAs.
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Table 3: Small RNA Extracted from Fresh-Frozen Tissue Biopsies1 2
Total small
RNA (ng)

microRNA
(ng)

Total small
RNA (ng)

microRNA
(ng)

Total
microRNA
small
(ng)
RNA (ng)
Third Extraction
------------158.4
9.45
------------------------548.37
323.73
----1558.92
1077.36
-------------------------------------------------------------------------------------------------

Patient
First Extraction
Second Extraction
Sample
1T
1634.49
1063.08
----2T
1373.13
857.97
699.75
112.68
3T
1355.25
983.835
----4T
205.38
9.9
170.64
21.87
5T
1043.73
192.24
----6T
281.205
51.435
310.41
49.05
7T
311.985
171.225
145.26
33.93
9T
977.85
694.17
343.08
97.56
11T
4027.68
2616.84
----12T
856.35
222.66
1443.375
860.445
13T
1351.53
758.97
834.93
648.18
15T
1013.85
539.73
1274.7
930.36
16T
291.21
45.66
1874.85
1232.76
17T
1869.57
944.28
1468.86
723.18
18T
1270.89
690.21
----19T
2087.19
1222.56
1769.22
1352.82
20T
2736.18
1633.5
1108.8
506.7
21T
2747.07
1585.08
1406.76
1089.9
22T
1292.49
885.15
----23T
1314.45
829.71
----24T
1849.23
1087.29
578.31
406.5
25T
1368.54
558.18
----26T
3317.49
1990.53
406.53
141.39
27T
1807.74
823.23
718.92
472.59
28T
726.75
495
587.88
282.84
29T
1729.26
1032.39
----30T
362.07
61.92
----31T
1728.54
1109.16
----32T
1674.36
889.65
2028.33
1523.565
33T
981.18
512.19
----34T
529.83
221.49
1951.83
965.16
35T
1541.97
1224.27
----36T
5867.46
3882.06
1812.6
1243.35
37T
986.4
402.345
1346.31
658.98
38T
8096.085
5249.16
3351.24
1851.03
39T
1016.505
390.645
----40T
4171.14
1201.77
255.825
70.335
1
Agilent Bioanalyzer small RNA chip
2
Samples indicated in boldface were used for cDNA library preparation.
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Figure 2: Construction of cDNA libraries from Serum and Tissue small RNAs
Small RNAs are hybridized with a mix of 5’ and 3’double-stranded DNA/RNA adaptors
which contain 5’ and 3’ single-stranded extensions composed of degenerate bases. These
extensions allow adaptor binding to all small RNAs within a sample. Following singlestrand synthesis and a size-selection protocol, a series of adaptors are added to the 5’ and
3’ ends of the small RNA products. The A Adaptor and Key Sequence together are 30bp.
The unique barcode sequence is 10bp. The 10 bp Internal Adaptor contains the 5’ primer
binding site. The P1 Adaptor is 30bp in length. (Michael Zianni, Thermo Fisher
Scientific, Personal Communication).
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increased ethanol concentration. However, for the serum samples, this first step was
deemed unnecessary due to the assumed low input RNA concentrations. Therefore, the
small RNA library size selection protocol from the Total Exosome RNA and Protein
Isolation kit (#4478545, Life Technologies) was utilized for the serum derived cDNA
libraries. This protocol simply requires binding of the small RNA products to nucleic acid
binding magnetic beads, a wash step to remove larger RNA products, and then elution
into 10ul nuclease free water.
Following size-selection for small RNA products, three new adaptors were added during
PCR amplification of the cDNA library (Figure 2). The 5’ A adaptor was 40 base pairs in
length and included one of 16 unique barcodes. This 10bp barcode sequence was
essential to differentiate among cDNA libraries following small RNA-seq. A 5’ 10 bp
internal adaptor provides the binding site for the 5’ PCR primer. The P1 adaptor is 30bp
in length and added to the 3’ ends of the library fragments. The A and P1 adaptors are
necessary for small RNA-seq. After amplification of the cDNA libraries by PCR, another
size-selection step identical to the first occurs. The yield and size distribution for each
purified cDNA library is then assessed in a quality control step via an Agilent
Bioanalyzer DNA1000 chip.
Selection of cDNA libraries for small RNA-sequencing
Concentration of microRNA products in each cDNA library was determined by an
Agilent 2100 Bioanalyzer (Figure 3). Since the adaptors and barcode total to 80 base
pairs (Figure 2), cDNA library fragments derived from microRNAs (14-24bp) are
expected to be between 94 – 114 bp [172]. Ideally, only those cDNA libraries which
42
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Figure 3: cDNA library Selection is Based on the size of the 94-114bp peak
Representative cDNA libraries constructed from patient tissue biopsy (Agilent
Technologies DNA1000 chip). The first peak at 15bp and the last peak at 1500bp are an
internal DNA standards provided in the Agilent Bioanalyzer DNA1000 chip kit. (A) A
representative ideal cDNA library. Large peak at 94-114bp indicates a large
concentration of microRNA products. The small peak adjacent to the 94-114bp peak was
the adaptor-dimer peak. Any peaks above 300bp were other small RNAs. (B) A
representative suboptimal library. The second largest peak at 89bp is considered the
adaptor-dimer peak.
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possessed a single large peak in this size range were selected for small RNA-seq. Peaks
occurring before 94 base pairs were believed to belong to adaptor dimers. High
concentrations of adaptor dimers, as depicted in Figure 3B, were thought to skew the
sequencing results. Peaks after 114 base pairs generally were considered contamination
by small RNAs, including tRNAs, indicating reduced effectiveness in size-selection
during cDNA library construction.
To maintain an appropriate number of patients per pathology group for sufficient
statistical power, suboptimal cDNA libraries were included in the small RNA-seq
experiments (Appendix II). 93 cDNA libraries derived from 69 serum or tissue samples
were sequenced. Of those, several cDNA libraries were considered suboptimal as they
contained large adaptor-dimer peaks. It became evident that small RNA-seq of cDNA
libraries with large adaptor dimer peaks and small peaks at 94-114bp did not necessarily
result in reduced sequencing of microRNA products (Appendix II). Some cDNA libraries
with only the one large peak between 94-114 base pairs still sequenced large amounts of
adaptor dimers and were not guaranteed to have high microRNA read counts in each
sample. In this study, the peak trace provided by the Agilent 2100 Bioanalyzer was not a
useful predictor of how well a cDNA library would sequence, in terms of microRNA read
counts.
Small RNA-seq of cDNA libraries prepared from Patient Serum and Fresh-Frozen Tissue
Small RNA-sequencing was performed on the Ion Proton Next Generation Sequencing
instrument using the Ion PI Hi-Q emulsion PCR and sequencing kits. Up to 14 cDNA
libraries were pooled for each small RNA-seq run. The selected cDNA libraries were first
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diluted to 5nM. The pooled cDNA libraries were then diluted to a final concentration
ranging from 5pM-20pM.
Even though the same concentration of cDNA library was included for each sample in
each small RNA-seq run, it was observed that some samples sequenced substantially
more microRNA read counts than others on the same Ion PI sequencing chip. In instances
where this occurred, the samples that did not sequence well were sequenced on another
chip and the pooled library concentration was increased to allow for more overall total
reads per chip. Initially, the 5pM pooled library concentration was intended to limit the
number of reads sequenced by adapter dimers. However, the percentage of adapter dimer
sequenced did not increase dramatically when the pooled library concentrations were
increased to 15pM or 20pM (Appendix I).
After sequencing 93 cDNA libraries over 16 small RNA-seq runs, a quality control step,
the Ion Torrent smallRNA_analysis plugin, obtained a measure of microRNA reads
sequenced for these cDNA libraries (Appendix II). This preliminary analysis aligned and
quantitated the sequences for each sample to miRbase v20 [173, 174]. The number of
microRNA reads for a cDNA library ranged from 16,829 – 13,538,600 reads (Appendix
II). 21 cDNA libraries sequenced more than 1,000,000 microRNA reads, the threshold
generally suggested by the manufacturer of the sequencing instrument. These libraries did
not include enough of each pathology group to maintain sufficient statistical power in
downstream analyses. To address this, the minimum microRNA read count threshold to
select cDNA libraries for analysis was reduced to 200,000 microRNA reads. The 55
cDNA libraries that passed this threshold included 12 BE, 10 EAC, 14 GERD, 10 LGD,
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and 9 Normal serum or tissue samples (Appendix II). Due to the high variability in
microRNA expression within the Normal patient group (Appendix III), the nine Normal
samples were excluded from the analysis of the small RNA-seq data. The remaining 46
cDNA libraries comprised of 25 serum samples and 21 tissue samples. Each stage of BE
pathogenesis was represented by at least 5 patients (Table 4).
The small RNA sequences from the 46 samples selected from this quality control step
were converted to microRNA read counts in Partek Flow®. The small RNA sequences
could originate from a variety of small RNA products, not just microRNA products.
Therefore, sequences were aligned and quantitated to miRBase v.21 [144, 145]. This
provided the raw read counts for all 2,588 known human microRNAs in each patient
sample (Table 5).
Normalization of microRNA read counts by Trimmed Mean of M-values (TMM)
Total microRNA reads in each patient sample is variable, and this can affect downstream
statistical analysis. To ensure all samples are comparable, a normalization method is
applied to the microRNA read counts obtained after alignment and quantification to
miRBase v.21.The Trimmed Mean of M-values (TMM) normalization method has a
precedent for use with RNA sequencing [148-150]. The majority of microRNAs in the 25
patient serum samples and the 21 patient tissue samples had 0-10 read counts (Figure 4).
The similarities among the microRNA read count distributions for each sample indicated
that most genes are not differentially expressed among the four pathology groups. This is
an important observation, as TMM is only an appropriate normalization method for those
data where a small fraction of genes are differentially expressed in an experimental group
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Table 4: Composition of Serum and Tissue Sequencing Data Sets

1

Pathology

Serum Samples (n)1

Tissue Samples (n)1

GERD

8

6

BE

7

5

LGD

5

5

EAC

5

5

25

21

20 Serum and Tissue came from the same patients.
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Table 5: Selected Serum and Tissue Samples Processed and Aligned in Partek Flow

1

Sample

Pathology

Total microRNA
reads1

Sample

Pathology

Total microRNA
reads1

13S

EAC

204,003

13T

EAC

449,663

15S

BE

413,519

15T

BE

345,976

16S

LGD

183,935

16T

LGD

335,729

17S

LGD

282,797

17T

LGD

1,026,395

18S

BE

556,967

1T

BE

300,635

19S

GERD

223,628

20T

BE

1,400,802

1S

BE

883,503

21T

GERD

309,603

20S

BE

1,227,629

23T

GERD

176,626

21S

GERD

2,420,358

26T

EAC

2,023,514

23S

GERD

1,277,820

27T

EAC

397,774

24S

BE

537,818

28T

LGD

1,246,450

26S

EAC

161,492

29T

BE

165,614

27S

EAC

135,689

2T

GERD

429,997

28S

LGD

152,250

32T

GERD

825,618

29S

BE

553,629

33T

BE

317,549

2S

GERD

302,725

34T

EAC

411,163

32S

GERD

525,009

36T

GERD

254,886

33S

BE

735,174

37T

LGD

2,881,190

34S

EAC

177,121

38T

EAC

1,977,969

36S

GERD

1,236,167

39T

LGD

512,297

37S

LGD

4,239,575

6T

GERD

1,089,611

38S

EAC

371,094

39S

LGD

1,109,802

3S

GERD

664,552

7S

GERD

2,969,782

Raw microRNA reads generated in Partek Flow
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Figure 4: Distribution of Raw MicroRNA Read Counts in Serum and Tissue
Samples
Processing of small RNA sequencing and conversion to microRNA read counts was
performed in Partek FlowTM. Each barplot was generated in Partek FlowTM. Each cDNA
library sample was coded with a unique color. The y-axis is the number of known human
microRNAs which occur in a sample for each read count category (x-axis). (A) Serum
dataset (25 samples) following base trimming, alignment to miRbase v21, and
quantification to miRbase v21. (B) Tissue dataset (21 samples) following base trimming,
alignment to miRbase v21, and quantification to miRbase v21
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[149]. TMM equates overall expression of all genes within the libraries, thereby
decreasing the rates of false positives when analyzing the data for differential microRNA
expression [149]. First, for a given microRNA, a ratio (x) between the raw microRNA
read counts in each sample to the total number of read counts in that same sample were
calculated:

𝐹𝑜𝑟 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑚𝑖𝑐𝑟𝑜𝑅𝑁𝐴 𝑖𝑛 𝑎 𝑠𝑎𝑚𝑝𝑙𝑒: 𝑥

=

𝑚𝑖𝑐𝑟𝑜𝑅𝑁𝐴 𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡𝑠
𝑡𝑜𝑡𝑎𝑙 𝑟𝑒𝑎𝑑𝑠

Log-fold changes for each microRNA (M-values) compared these ratios between a given
sample and a randomly selected reference sample [149].

𝑀

= 𝑙𝑜𝑔

𝑥
𝑥

Absolute expression levels (A-values) were also calculated for each microRNA in each
sample [149]:

𝐴

=

1
𝑙𝑜𝑔
2

𝑥

× 𝑥

Then, the M-values were trimmed by 30% and the A-values by 5% on both ends. The
TMM normalization factor applied to the data set is derived from the weighted mean of
trimmed M-values [149]. Since some of the 2,588 microRNAs displayed no expression in
some of the serum and tissue samples, it was necessary to add an offset value of 1.00 to
prevent non-zero errors in the TMM normalization.
All subsequent data analyses were performed on the TMM-normalized microRNA read
counts for the patient serum and patient tissue samples.
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Applying a Minimum Normalized microRNA Read Count Filter to Serum and Tissue
Datasets
To ensure the candidate microRNAs revealed by these analyses were selected based on
sufficient statistical power, a filter based on normalized microRNA read counts was
applied to the serum and tissue datasets. For a given microRNA, 25% of the patient
samples needed to contain 100 or more normalized microRNA read counts. microRNAs
with 100 or more normalized read counts would be more likely to be detected by qPCR
during validation experiments [151]. This filter removed any microRNAs that had low
expression in every pathology group. Allowing for 25% of the samples to exhibit low
normalized read counts enabled capture of any candidate microRNAs which might be
lowly expressed in only one pathology group. For the serum and tissue datasets, the
normalized 100 microRNA read count filter removed all but 187 and 272 microRNAs,
respectively.
Identification of Candidate microRNA Biomarkers for BE Pathogenesis in Patient
Serum and Tissues
The filtered TMM-normalized microRNA read counts for the serum and tissue data sets
were analyzed separately by three different methods: unsupervised hierarchical
clustering, Nearest Shrunken Centroids classification, and the randomForest classifier.
The objective of these analyses was to reveal any potential microRNA signatures in the
serum or tissue datasets which could differentiate all four stages of BE pathogenesis.
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Hierarchical Clustering
In hierarchical clustering, samples are clustered based on the extent of their similarities to
each other. Similarities are determined by the Euclidean distances between microRNA
read counts for each sample [175]. Clustering was based on the average Euclidean
distances for all data points between two clusters, a method called average linkage [176].
Hierarchical clustering for this study was performed in Orange Dating Mining Tool Box
v. 3.20.1 and visualized as a dendrogram [152]. For the serum dataset, all 187 filter
microRNAs were included in four distinct clusters (Figure 5A). In terms of pathology,
the four clusters of serum samples were very heterogenous and a relationship between BE
pathogenesis and microRNA expression was not apparent. When hierarchical clustering
is applied to the 25 tissue samples, two larger clusters can be observed (Figure 5B).
However, these clusters are also heterogenous in terms of pathology, and do not include
six of the tissue samples. These six tissue samples consist of 1 GERD, 3 LGD, and 2
EAC. It appears that normalized microRNA read counts cannot be used to group tissue
samples based on pathology, according to this hierarchical clustering analysis.
Visualization of the serum and tissue data sets by heat mapping demonstrates the
difficulty of identifying microRNA signatures from 187 microRNAs or 272 microRNAs,
respectively (Figure 6). In the heat maps, k-means clustering separates the microRNAs
into a pre-determined number of clusters, based on proximity to calculated centroids
[177, 178]. The centroid of a cluster is a point where the Euclidean distances among the
data points are minimized. If a microRNA signature existed in either the serum or tissue
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Figure 5: Hierarchical Clustering of Serum and Tissue Samples
Hierarchical Clustering was performed and visualized in Orange Data Mining version
3.20.1. Metrics used: Euclidean Distances and Average Linkage. (A) 25 serum samples
clustered based on normalized microRNA read count data for 187 filtered microRNAs.
(B) 21 tissue samples clustered based on normalized microRNA read count data for 272
filtered microRNAs.
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Figure 6: Heat Maps of Serum and Tissue Samples
Heat Maps were constructed in Orange Data Mining version 3.20.1. k-means clustering
(10 clusters) was used to group microRNAs. (A) 25 serum samples (x-axis) vs normalized
microRNA read count data for 187 filtered microRNAs (y-axis). (B) 21 tissue samples (xaxis) vs normalized microRNA read count data for 272 filtered microRNAs (y-axis).
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data sets, it was expected that a cluster of microRNAs would display distinct differential
expression in the heat map among the four stages of BE pathogenesis.
Nearest Shrunken Centroids
A classifier termed Nearest Shrunken Centroids (NSC) was used as an alternative to
hierarchical clustering. NSC has been utilized previously to identify several genes which
differentiate multiple types of round blue cell tumors [156]. NSC is advantageous in
analyzing data with numerous variables and a significantly smaller number of samples,
which described the serum and tissue small RNA-seq datasets.
NSC was implemented through the PAMR package available for R. For each microRNA
in each sample, a centroid was calculated for each pathology group by dividing the
average microRNA expression by its standard deviation. NSC is a supervised classifier,
in that the groups must be defined beforehand. Then for each pathology group, the
centroids were “shrunk” towards zero by a certain threshold value [156]. This threshold
value is associated with a misclassification error percentage. Each microRNA was given
a score based on their distance from the centroid after shrinkage. NSC outputs a
combination, or signature, of microRNAs which can differentiate the predefined
pathology groups from each other. If a microRNA possessed a non-zero score for a
pathology group, that microRNA contributed to the signature’s ability to differentiate that
pathology group from the other three pathology groups.
When NSC was applied to the serum dataset, 185 of the 187 microRNAs showed nonzero scores for at least one pathology (Figure 7). This indicates that these 185
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Figure 7: Serum microRNAs cannot distinguish among Four Stages of BE
Pathogenesis
Nearest Shrunken Centroids (PAMR package in R) analysis applied to 25 Serum
samples, based on TMM-normalized read counts for the 187 filtered microRNAs. A
representative sample of 185 microRNAs are shown here. These 185 microRNAs were
associated with the least number of misclassification errors for each pathology group in
the NSC analysis and an overall misclassification rate of 44.6%.
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microRNAs could operate together as a microRNA signature to differentiate every
pathology group in BE pathogenesis. However, the overall misclassification rate for these
microRNAs was 44.6%. The misclassification rates for each pathology group ranged
from 20% -80%. While many serum microRNAs may be differentially expressed in BE
pathogenesis according to the NSC analysis, the misclassification rate is too high for
these microRNAs to function as a signature for every stage of BE pathogenesis.
In the tissue dataset, 23 of the 272 microRNAs have non-zero scores for one or more of
the four pathology groups (Figure 8). The overall misclassification rate for this analysis
was 47.5%. Most microRNAs in this potential tissue microRNA signature appear to be
specific to LGD or EAC. However, the misclassification rates associated with these
pathology groups was 40% and 80%, respectively. One microRNA had a non-zero score
for the GERD pathology group, miR-126-5p. No microRNAs were able to differentiate
the BE group from the other pathology groups, Therefore, this 23 microRNA signature
could not function as a biomarker panel for BE pathogenesis.
randomForest
A decision tree can separate tissue or serum samples into the pathology groups based on
the TMM-normalized microRNA read count data (Figure 9). A single decision is prone to
over-fitting [179]. randomForest is a supervised machine learning method which samples
with replacement from the dataset to build a “forest” of decision trees [154, 155]. Two
different randomForest techniques were utilized in this study: randomForest classification
and randomForest regression. The classification randomForest separates the samples into
previously assigned groups using 1 million decision trees created from the microRNA
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Figure 8: Tissue microRNAs cannot distinguish among Four Stages of BE
Pathogenesis
Nearest Shrunken Centroids (PAMR package in R) analysis applied to 21 Tissue
samples, based on TMM-normalized read counts for the 272 filtered microRNAs. These
23 microRNAs were associated with the least number of misclassification errors for each
pathology group in the NSC analysis and an overall misclassification rate of 47.5%.
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Figure 9: Decision Trees Can Separate Tissues into the Four Pathology Groups
Representative decision tree was generated in Orange Data Mining version 3.20.1.
from TMM-normalized read counts for six select microRNAs from the Tissue dataset
(21 total samples).
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read count data. The microRNAs are ranked by mean decrease accuracy, which indicates
the importance of a microRNA in constructing the randomForest. A high mean decrease
accuracy occurs if the accuracy of the model decreases when the microRNA is removed
from the randomForest. A measure of predictive error for this analysis is the out of bag
(OOB) estimate of error rate.
randomForest regression includes an extra component of sample order. Since BE
pathogenesis is a step-wise malignant progression, the pathology groups were numbered
sequentially with GERD being 1 and EAC being 4. Instead of Mean Decrease Accuracy,
a microRNA’s importance in the randomForest regression is indicated by the percentage
the mean squared error (%IncMSE) of the predictions increases as a result of removing
the microRNA. There is not an equivalent metric of OOB estimate of error rate for the
randomForest regression
randomForest classification
As can be observed in Figure 10A, miR-190a-5p is considered the most important
microRNA in classifying the 25 serum samples into the four pathology groups. The 64%
OOB estimate of error rate for the serum randomForest classification was not due to a
misclassification of any particular group. All the pathology groups had at least 50% of
their samples misclassified into the incorrect pathology group. Only LGD had a 100%
misclassification rate; all 5 samples misclassified as either EAC, BE, or GERD.
miR-196b-5p and miR-196a-5p are the top two most important microRNAs for
classifying the four pathology groups, according to the tissue randomForest classification

67

analysis (Figure 10B). Here, the OOB estimate of error rate was 67%. All 5 EAC tissue
samples misclassified as either BE or LGD, and four out of six GERD samples
misclassified as either EAC, LGD, or BE. As in the serum analysis, no single pathology
group contributed to the large OOB estimate of error rate.
Since randomForest separates data into groups using decision trees, it will tend towards a
focus on all variability in the data, rather than just the differences between pathology
groups. This is especially true when less than 5 groups are assigned in a dataset. This may
account for why even the most important microRNAs from the serum or tissue datasets
were not good classifiers of BE pathogenesis.
randomForest regression
In the serum analysis, miR-190a-5p, miR-194-5p, and miR-106b-3p had the highest
%IncMSE values. These microRNAs appeared to be the most important microRNAs in
accurately predicting a sample’s pathology and its order in BE pathogenesis (Figure
11A). In tissue, miR-196b-5p, miR-223-3p, and miR-196a-5p rank most highly,
according to their %IncMSE values (Figure 11B).
Conclusions
It was clear from the hierarchical clustering and NSC analyses that a microRNA
signature for BE pathogenesis was not detectable in the serum data sets. The NSC
analysis of the tissue data set did provide a large potential signature of microRNAs which
could differentiate all four stages of BE pathogenesis. However, this was associated with
high misclassification rates for each pathology group. While several serum and tissue
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Figure 10: randomForest classification on Serum and Tissue datasets
randomForest classification was performed in the randomForest package available for R.
(A) 187 Filtered Serum Samples. (B) 272 Filtered Tissue Samples
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Figure 11: randomForest regression on Serum and Tissue datasets
randomForest regression was performed in the randomForest package available for R. (A)
187 Filtered Serum Samples. (B) 272 Filtered Tissue Samples
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microRNAs ranked as the most important classifiers for BE pathogenesis in the
randomForest analyses, misclassification rates for each pathology were still not ideal.
For this study, a microRNA signature for BE pathogenesis was not readily apparent in
either the serum or tissue samples when analyzed by hierarchical clustering, NSC, or
randomForest.
Gene Specific Analysis Identifies Single Candidate microRNAs through Pair-Wise
Comparisons
Gene Specific Analysis (GSA) in Partek Flow allows for comparisons between two
groups in a data set and generates a p-value for each of the 2,588 microRNAs aligned to
miRBase v21, based on a selected statistical model. This GSA tested differential
expression between BE vs GERD, LGD vs BE, EAC vs BE, and EAC vs LGD. The EAC
vs BE comparison was included as BE patients can progress quickly through the LGD
step to develop EAC.
Since GSA entails multiple comparisons, a Bonferroni correction is necessary to
establish a limit to Type I statistical errors [180]. This correction entails dividing an α
value by the number of pair-wise comparisons. The α describes the permissible false
positive rate, while the number of pair-wise comparisons are those microRNAs which
passed the minimum read count filter.
Serum
When a false positive rate of 5% was permitted ( = 0.05), none of the microRNAs
passed the Bonferroni threshold applied to the GSA results. When  was increased to 0.1,
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only miR-194-5p showed significant downregulation in serum of EAC patients in
comparison to BE patients (Table 6). This indicates that differential microRNA
expression among the four stages of BE pathogenesis cannot be detected in the 24 patient
serum samples. miR-194-5p is in the top four and the top two most important
microRNAs in the serum randomForest classification and regression analyses,
respectively. miR-194-5p has previously been found to have increased expression in
tissue and serum of BE patients [94].
Tissue
Of the 272 microRNAs, only three passed the Bonferroni threshold with  set to 0.05
(Table 6). Three additional microRNAs were included when  was reduced to 0.1 (Table
6). miR-196a-5p, miR-196b-5p, and miR-215-3p were all upregulated in BE patient
tissues when compared to the 6 GERD patient tissues. miR-596 showed downregulation
in EAC patient tissues, in comparison to LGD. However, miR-596 did not pass the
Bonferroni threshold in the BE vs EAC comparison. Expression of miR-223-3p was 15fold higher in the EAC vs BE patients. miR-4655-3p was downregulated in EAC vs BE.
Yet, neither miR-223-3p nor miR-4655-3p were found to be significantly differentially
expressed in either the BE vs LGD or EAC vs BE comparisons. In previous studies, miR196a-5p, miR-196b, miR-215, and miR-223 have all been shown to be upregulated in BE
tissues [94].
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Table 6: Seven microRNAs display Differential Expression in Stages of BE pathogenesis
microRNA

Adjusted p-value1

Fold Change

miR-194-5p

0.05928

-6.74

0.05

miR-196b-5p

0.00048

23.20

0.05

miR-196a-5p

0.01994

18.30

0.1

miR-215-3p

0.05930

37.90

α
Serum (BE vs EAC)
0.1
Tissue (BE vs GERD)

Tissue (LGD vs BE)
0.1

None Passed Threshold

Tissue (EAC vs BE)
0.05

miR-223-3p

0.00588

15.00

0.1

miR-4655-3p

0.05930

-15.10

miR-596

0.06174

-13.00

Tissue (EAC vs LGD)
0.1
1

p-values Bonferroni-corrected for multiple comparisons.
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randomForest analysis of BE and GERD Tissue Samples support Findings from Gene
Specific Analysis
miR-196a-5p and miR-196b-5p were identified as important microRNAs for overall
classification of the tissue samples into the four pathology groups, according to both
randomForest analyses (Figures 10 and 11). miR-223-3p, miR-4655-3p and miR-596 also
appear to be the top 20 most important microRNAs in the tissue randomForest analyses.
To determine how well the microRNA candidates from the GSA classify the samples into
their corresponding pathology groups, miR-196a-5p, miR-196b-5p, and miR-215-3p
were analyzed again by randomForest classification. Instead of including all four
pathology groups, only BE and GERD tissues were included in this follow-up analysis.
miR-196a-5p and miR-196b-5p ranked first and fourth among the 272 microRNAs,
indicating their ability to differentiate BE and GERD. When the input data is limited to
only the three microRNAs of interest, 1 out of 5 BE samples and 0 of 6 GERD samples
were misclassified. The overall error rate for these microRNAs was 9.09%. As only 5-6
patient samples are included in each pathology group, the randomForest analyses were
not particularly robust validation methods for the GSA results. Analysis of only these
three microRNAs in the BE and GERD groups by hierarchical clustering or heat mapping
did not reveal clustering based on pathology. The randomForest classifier does lend
further support to the candidacy of these microRNAs as biomarkers. Since the small
sample size of the small RNA-seq study prevents validation by in silico methods, a qPCR
study on a larger sample set is necessary to validate the candidate microRNA biomarkers.
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Validation of Small RNA-Sequencing Results by Quantitative real-time PCR
Preparation of cDNA libraries for small RNA-seq and the sequencing technology itself
can introduce technical biases to data [181]. Therefore, it is necessary to confirm small
RNA-sequencing results by another technique [182]. qPCR is a technique renowned for
its accuracy and specificity in RNA expression [183]. It is considered the obligatory
technique for validation experiments for small RNA-sequencing studies.
The three BE vs GERD microRNA candidates were chosen for qPCR validation in this
study. miR-196b-5p, miR-196a-5p, and miR-215-3p have the lowest p-values of all the
microRNAs which passed either of the Bonferroni correction thresholds. All three of
these microRNAs are significantly upregulated in the BE patient tissues when compared
to the GERD patient tissues (Table 6). GERD is estimated to affect 20% patients in the
United States [184]. Since BE lesions do not present additional symptoms, the actual
number of GERD patients with BE is unknown. GERD patients with undiagnosed BE
still have the same heightened risks of dysplasia and EAC but do not undergo
surveillance. The three BE vs GERD candidates could become confirmatory biomarkers
for BE in GERD patients.
Since the small RNA-seq study included a small number of human patient samples, the
variance in microRNA read counts, even in the same pathology group, could be large.
For example, the variance among microRNA read counts in the BE patients was
noticeably larger than the variance in the GERD patients, especially for miR-215-3p
(Figure 12). The heightened variability in the BE tissues for miR-215-3p may account for
why this microRNA did not pass the Bonferroni threshold when  = 0.05.
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miR-196a-5p

miR-196b-5p

miR-215-3p
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Figure 12: Three microRNAs show significant increased expression in BE Tissues vs
GERD Tissues
TMM-normalized microRNA reads counts obtained by small RNA-seq for the three BE
vs GERD candidate microRNAs show increased expression and larger variance in the BE
patient tissues.
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Power Analyses of Tissue microRNA Candidates
A separate cohort of formalin-fixed paraffin-embedded (FFPE) tissues from 13 GERD
and 13 BE patients was utilized for the qPCR validation studies. The sample number (n)
of these studies was selected based on power analyses performed for each of the three
candidate microRNAs (Table 7). These analyses were done using the GERD vs. BE
microRNA read counts obtained from the small RNA sequencing libraries (Table 7).
Though miR-196a-5p and miR-196b-5p required eight and seven samples to achieve 80%
power, 13 samples per pathology group were needed to achieve sufficient statistical
power for miR-215-3p.
Total RNA Extraction from Formalin-Fixed Paraffin-Embedded Tissues required
Optimization
Total RNA was extracted from the FFPE tissues by the Covaris truXTRAC FFPE RNA
microtube kit which utilizes the Covaris M220 Acoustic Focused ultra-sonicator. Initial
total RNA extractions contained guanidine ITC contamination, noted upon assessment by
NanoDrop ONE. Guanidine salts are a component of the Covaris kit necessary for the
column chemistry. Total RNA was re-precipitated from these samples using a sodium
hydroxide/ethanol precipitation protocol. Subsequent total extractions included a third
wash with the Covaris ethanol wash buffer, which appeared to resolve the guanidine salt
contamination. Total RNA concentration was obtained by NanoDrop ONE (Table 8).
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Table 7: Power analysis for qPCR validation
TMM-Normalized microRNA Read Counts

Samples Required2

microRNAs

GERD (mean)

BE (mean)

Standard
Deviation

miR-196a-5p

26.43

484.09

305.22

8

8

miR-196b-5p

18.89

438.03

264.20

7

7

miR-215-3p

12.77

483.61

410.24

13

13

1

GERD (n)

BE (n)

1

MicroRNAs identified as differentially regulated in the GERD vs. BE comparison in
tissue samples based on small RNA-seq data.

2

Minimum number of samples required to obtain power of 0.8 with an σ of 0.05.
Power analyses based on TMM-normalized microRNA read counts from tissue small
RNA-seq
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Table 8: Total RNA Extracted from Formalin Fixed Paraffin Embedded Tissues1
Sample Name
3524B
2925B
2427F
2401B
505E
4176B
3983D
3694C
766E
5138C
1507F
2244C
1689G
1823H
1976B
2374C
4268E
24931849B
2870A
2024A
5791B
5281D
1927B
1923E
1833A
6302D
5751A
5307C
1

2

Pathology
BE
BE
BE
BE
BE
BE
BE
BE
BE
BE
BE
BE
BE
BE
BE
GERD
GERD
GERD
GERD
GERD
GERD
GERD
GERD
GERD
GERD
GERD
GERD
GERD
GERD

Total RNA2
(ng)
1,152
826
1,082
1,344
2,763
1,050
1,180
385
749
1,306
1,054
1,985
1,750
529
1,432
2,114
977
830
1,050
221
1,428
1,876
567
1,687
1,316
2,027
872
557
532

Absorbance2
2260/280
1.83
1.83
1.86
1.88
1.93
1.90
1.87
1.71
1.82
1.86
1.90
1.93
1.90
1.72
1.90
1.82
1.69
1.76
1.65
1.64
1.65
1.67
1.60
1.81
1.70
1.85
1.74
1.64
1.67

Absorbance2
260/230
1.03
1.41
1.59
1.73
1.94
1.26
1.68
1.98
1.29
1.53
1.79
1.78
0.57
2.16
1.64
2.16
2.25
2.05
2.09
1.67
1.95
1.22
1.23
1.54
1.35
1.74
1.36
1.06
0.90

Extracted by Covaris TruXTRAC FFPE RNA microTUBE kit (Covaris M220 Focused
Ultrasonicator)
Measured by NanoDrop ONE spectrophotometer
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Quantitative real-time PCR for 13 GERD and 13 BE Tissue Samples
cDNA for the qPCR experiments was synthesized from 10ng total RNA by the TaqMan
Advanced microRNA cDNA synthesis kit. Since no quality control step is included to
assess cDNA quantity and quality prior to qPCR, the 10ng starting amount is necessary to
ensure a common baseline among the 26 samples.
In this study, each microRNA was assessed in triplicate for each BE and GERD sample.
Ct values for the biological replicates were the average of the technical replicates. Since
the analysis utilized, the ΔΔCt method, is a relative quantitative method, an endogenous
control microRNA was chosen to normalize the data from the three experimental
microRNAs. miR-423-5p did not show significant differential expression between the
GERD and BE patient tissues in the small RNA-seq experiments (Figure 13). In the
qPCR experiments, miR-423-5p expression significantly differed in the BE FFPE tissues
when compared to the GERD FFPE tissues. However, this difference was in the same
direction as the expression difference for the three experimental microRNAs (Figure 14).
While this indicated that miR-423-5p was not a perfect control microRNA for qPCR in
distal esophageal tissues, its effect on the overall results of the ΔΔCt calculations
appeared to have been minimal.
After the average Ct values for each experimental microRNA are normalized to miR-4235p, a Student’s T-test was performed on the ΔCt values. It should be noted that the lower
the Ct value, the more abundant and more highly expressed the microRNA in the tissue
sample. As shown in Figure 15, miR-196b-5p showed the most significant difference
between GERD and BE tissues, followed closely by miR-215-3p. In the small RNA-seq
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miR-423-5p: Tissue small RNA-seq

p-value = 0.8919
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Figure 13: miR-423-5p is not significantly differentially expressed between GERD
and BE tissues
TMM-normalized microRNA reads counts for miR-423-5p were obtained by small RNAseq. A Student’s t-test performed between GERD patient tissues and the BE patient
tissues for miR-423-5p produced a p-value of 0.8919. Box plot and Student’s T-test were
generated in R.
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Figure 14: miR-423-5p does not display constant expression between GERD and BE
FFPE tissues
Average Ct values for miR-423-5p were obtained by qPCR. Student’s t-tests performed
between GERD patient tissues and the BE patient tissues for miR-423-5p and three
experimental microRNAs produced the following p-values: *: p-value = 4.87 x 10-2 **:
p-value =6.84 x 10-3 ***: p-value= 6.01x10-6 ****: p-value= 3.42x10-6
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Figure 15: miR-196a-5p, miR-196b-5p, and miR-215-3p all display significantly
increased expression in BE tissues in comparison to GERD Tissues
Average Ct values for each microRNA were obtained by qPCR. ΔCt values for each
microRNA were normalized to miR-423-5p. A Student’s t-test was used to calculate pvalues for pair-wise comparisons between GERD patient tissues and the BE patient
tissues.
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and randomForest results, miR-196b-5p was also the most significantly changed between
GERD and BE, thus this microRNA is a compelling candidate tissue biomarker for BE in
GERD patients.
Expression fold change (2-ΔΔCt) was calculated for each microRNA. As expected, all were
upregulated in BE vs. GERD (Table 9). The significant changes in the expression levels
of these microRNAs indicate that miR-196b-5p, miR-215-3p, and miR--5p are
potential tissue biomarkers for BE in GERD patients.
Gene Target Analysis Reveals Potential Regulation of Homeotic Genes by
Candidate microRNAs
MicroRNAs can be utilized as clinical biomarkers to diagnose disease; however, they
also can be utilized to increase understanding of a disease’s molecular mechanisms. For
each candidate microRNA, lists of predicted gene targets from TargetScan Human 7.2
and miRDB were compared to experimentally-validated targets found through TarBase
v8 and miRNet [145, 162, 165-167, 185]. Preference was showed for those predicted
gene targets which were also experimentally-validated. Additional insight into the impact
of the candidate microRNAs on the molecular mechanisms behind BE development was
gained through PubMed.gov literature search.
BE vs GERD candidate microRNAs: miR-196a-5p, miR-196b-5p, and miR-215-3p
miR-196a-5p and miR-196b-5p show similar but not exact microRNA read counts in the
5 BE and 6 GERD patient tissue samples. The sequences for these two mature
microRNAs differ by only a single nucleotide [186]. However, the two genes, MIR-196a-
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Table 9: Change in Expression of selected microRNAs in BE vs. GERD FFPE tissues.
microRNA

ΔΔCt1

Expression Fold Change2

miR-196a-5p

-2.49

+5.62

miR-196b-5p

-4.92

+30.33

miR-215-3p

-4.38

+20.79

1

ΔΔCt = ΔCtBE – ΔCtGERD
2
Expression Fold Change = 2-ΔΔCt
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1 and MIR-196a-2, which can generate miR-196a-5p are located on Chromosome 12 and
17. miR-196b-5p is a product of the MIR-196b gene on Chromosome 7.
The gene target analysis for both microRNAs showed midcluster and posterior HOX
genes from the A, B, and C clusters as common targets (Table 10). miR-196a-1 and miR196b-1 are located intergenic to the HOXB and HOXC clusters, respectively [186]. The
genes are both located in between the HOX9 and HOX10 genes. Due to the collinearity
of HOX genes, their position could indicate that the microRNAs are transcribed when
posterior HOXB and HOXC genes are activated. miR-196b is located intergenic to the
posterior genes of the HOXA cluster.
Gene targets for miR-215-3p have not been well-studied. Both target prediction
algorithms did not return results for miR-215-3p. Investigations into TarBase v8 and
miRNet only produced one target, FOXO1, which was validated to be a target of miR215-3p by luciferase reporter assay [187]. FOXO1 is also an experimentally-validated
target of miR-196a-5p [188]. An additional literature search revealed another target
validated by luciferase reporter assay: BMI1 [189]. BMI is considered a catalytic subunit
of the Polycomb Repressive Complex 1 (PRC1), a well-known silencer of HOX and
other developmental genes [190].
EAC vs BE candidate microRNAs: miR-223-3p and miR-4655-3p
miR-223-3p is a microRNA known to be dysregulated in numerous cancers, including
hepatocellular carcinoma, leukemia, lymphoma, and EAC [191-196]. The role of miR223-3p in cancer seems to vary depending on tissue type. In hepatocellular carcinoma,
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Table 10: Selected Gene Targets for the Three Candidate Tissue microRNA Biomarkers
miR-196a-5p targets
Gene

3’ UTR seeds

miR-196b-5p targets
Gene

3’ UTR seeds

miR-215-3p targets
Gene

3’ UTR seeds

HOXB71,2,4

1

HOXB71,2,4

1

FOXO12,4

1

HOXC81,2,3,4

4

RDX1,4

1

BMI15

δ

HOXA71,2,4

5

HOXC81,2,4

4

HOXB82,4

1

HOXA91,2,3,4

2

FOXO13,4

δ

FAS3,4

1

HOXA53,4

1

HOXA71,2

5

HOXA91

2

HOXA51,2

1

HOXB61

1

HOXB61,2

1

HOXB12

1

HOXB82

1

HOXB12

1

1

miRDB

2

TargetScan Human 7.2

3

DIANA TarBase v8

4

miRNet

5

Jones et al., 2015 [186]

δ Partial seeds or no seeds were indicated
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miR-223-3p is downregulated and is thought to take on a tumor suppressive role [191].
Streppel et al (2013) found that this microRNA displays a step-wise increase in BE
pathogenesis [196]. In that same study, overexpression of miR-223-3p in EAC cell lines
promotes migration and invasion. In the small RNA-seq data, miR-223-3p showed
significantly increased expression in the 5 EAC patients, in comparison to the 5 BE
patients (Table 6). However, significant differential expression was not observed between
LGD and BE or EAC and LGD.
miR-223-3p has hundreds of predicted and experimentally-validated gene targets. Input
of its gene targets found via the four methods into DAVID 6.8 Functional Annotation
tool indicated these genes play roles in FOXO, AMPK, and PI3K-Akt signaling [197].
miR-223-3p does not appear to directly target HOX genes from any of the four clusters.
miR-4655-3p is not a well-studied microRNA. None of its predicted targets from miRDB
or TargetScan Human 7.2 have been experimentally validated. Two studies have shown
that miR-4655-3p is differentially expressed in colorectal and triple negative breast
cancer cell lines [198, 199]. This may be due to the location of miR-4655, the gene
encoding miR-4655-3p, on chromosome 7. This gene is intragenic to the mitotic arrest
deficient 1 like 1 [200], the human homolog for the Drosophila MAD1 gene [200, 201].
MAD1L1 is a mitotic check point whose function is affected by chromatin instability in
cancer [200]. In colon cancer cell lines, this gene has been found to promote resistance to
doxorubicin [202]. The downregulation of miR-4655-3p in EAC may be due to decreased
transcription of the MAD1L1 gene in those tissues.
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EAC vs LGD candidate microRNAs: miR-596
The gene encoding miR-596 is in a portion of Chromosome 8 which is associated with
breakage in cancer [203, 204]. According to the initial gene target analysis, the only miR596 gene target validated by luciferase reporter assay has been LGALS3BP, a secreted
galectin-3 ligand [205]. Increased expression of this ligand is associated with poor
prognosis in cancers [205]. LGALS3BP is thought to activate components of ERK1/2
signaling, thereby promoting cell proliferation and inhibiting apoptosis [205]. A further
literature review concerning miR-596 procured another experimentally-validated target:
Smurf1 [206]. Smurf1 is a known negative regulator of p53, as it binds to and stabilizes
MDM2, a prominent p53 inhibitor [206]. The downregulation of miR-596 in EAC patient
tissues would lead to released MDM2 inhibition of p53 and increased expression of
LGALS3BP and its action on ERK1/2 signaling.
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DISCUSSION
Limitations in Identifying Biomarkers for BE pathogenesis
Identification of microRNA biomarkers in serum and tissue for clinical use faces
numerous challenges as there is no standardized methods for RNA extraction, cDNA
synthesis, or statistical analyses of differential microRNA expression [171, 207]. In this
study, no combination of microRNA biomarkers was found in the analysis of the small
RNA-seq data from either patient tissue or serum. This may be for multiple reasons.
Serum
Only one serum microRNA, miR-194-5p, could differentiate between two of the four
pathology groups in this study. miR-194-5p was significantly decreased in the serum of
EAC patients when compared to BE patients (Table 6). miR-194-5p was an important
microRNA in the classification and regression randomForest analyses (Figures 10 and
11) for the serum data set, indicating it may differentiate all four pathology groups from
each other. However, in the GSA for the serum data set, its expression was not
significantly different between the LGD and EAC groups or the BE and LGD groups.
miR-194-5p has been identified as an upregulated microRNA in tissue and serum of BE
patients in numerous previous studies [94].
Circulating microRNAs from serum or plasma have been used as diagnostic biomarkers
for many diseases and conditions, such as adult-onset Still’s disease, ectopic pregnancy,
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and hepatocellular carcinoma [208-210]. Success in identifying these microRNAs as
biomarkers may be based on the characteristics of the conditions studied. Some of these
conditions, such as adult-onset Still’s disease and ectopic pregnancy, are systemic.
Changes which occur throughout the body, rather than in a localized region, would be
more likely to generate a unique microRNA signature which could be associated with
that condition. Cancers like hepatocellular carcinoma can be localized to a single tissue
type. However, tumor-derived exosomes have been shown to provide a unique signature
in the bloodstream [211].
Chronic atrophic gastritis (CAG) bears many similarities to BE, as both diseases are
precancerous lesions characterized as an intestinal metaplasia in an anterior organ [112,
212]. Ten differentially expressed serum microRNAs have been detected in CAG, when
compared to chronic non-atrophic gastritis. Of these ten microRNAs, miR-148a-3p, miR320a, miR-451a, miR-486-3p, miR-486-5p, and miR-92a-3p showed similar though not
statistically significant differential expression in BE tissue and serum in comparison to
GERD patients. The difficulty in studying serum microRNAs in both diseases is that the
aberrant cell types are also present in the small intestine. Any microRNA signature
exported from the metaplastic lesions into the blood likely resembles the microRNAs
exported from the small intestine. This could obscure any microRNA biomarkers present
in the serum samples. CAG can proceed continuously through dysplasia to develop
gastric cancer [212]. The study that identified the ten serum microRNA biomarkers for
this disease did not include every stage in this progression. Instead, patients with CAG
were compared against patients with a related condition, chronic non-atrophic gastritis
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[212]. This allowed for a binary decision to occur without ambiguity among the groups
being compared.
BE pathogenesis is diagnosed as a step by step progression; however, it is a continuous
process. Although BE pathogenesis is separated into four pathology groups for this study,
the groups are not well delineated. The pathology groups do not describe how close each
patient was to entering the next stage of BE pathogenesis. BE is often not diagnosed
immediately upon formation of the lesions, and it is impossible to predict when each
patient will begin the transition to the next stage. Thus, using serum microRNAs to
cluster patients into four groups based on pathology was not successful in this study.
It was expected that, of the four pathology groups, EAC would have yielded significantly
differently expressed serum microRNAs. In the GSA, miR-194-5p was significantly
downregulated in EAC vs BE tissues. Eight microRNAs known to be differently
regulated in various cancers were included in the top twenty most important microRNAs
for the serum randomForest classification, randomForest regression, or both analyses
(Figures 10 and 11). None of these eight microRNAs were significantly differentially
expressed in any comparison in the GSA.
Serum is not the only biofluid available for non-invasive diagnosis of BE pathogenesis.
Four differentially expressed microRNAs have been detected in saliva of esophageal
cancer patients [213]. Three of these microRNAs, miR-144, miR-21-3p, and miR-451a,
showed similar, if not statistically significant, fold changes in the tissue of EAC patients
when compared to BE patients in this study. However, these trends were not observed in
the serum of EAC patients when compared to BE patients.
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Despite the limitations imposed by the biology of BE pathogenesis, serum microRNA
biomarkers for this disease may still be revealed if the technical limitations of this study
are addressed. This study was unique in that four stages of BE pathogenesis were
examined in serum samples. Five studies have identified serum microRNA biomarkers
for BE or EAC when compared against controls [129, 130, 214-216]. All these studies
utilized either qPCR on select microRNAs or microRNA qPCR arrays to detect
differential expression of serum microRNAs. In this study, qPCR was reserved for
validation of those serum microRNAs discovered by small RNA-seq.
For the serum cDNA libraries, small RNAs were extracted from 600ul serum for each
patient using the mirVana Paris RNA and Protein Isolation kit. The five previous studies
were able to extract enough microRNAs from 200-900ul serum for detection of
differential expression by qPCR [129, 130, 214-216]. In this study, the microRNA
concentration for each patient serum sample following small RNA extraction was
unknown. It is possible that extraction from 600ul serum simply did not provide enough
starting microRNA material for optimal small RNA-seq results. A kit optimized for
extraction of exosomes from serum samples may be more suited for this type of study.
The threshold chosen for the quality control step following small RNA-seq was 200,000
microRNA reads, as assessed by the Ion Torrent smallRNA_analysis plugin. This
threshold was selected in order to increase the number of tissue and serum samples
included in each pathology group for data analysis. However, a 200,000 microRNA reads
threshold may have been too low and allowed for numerous Type II statistical errors. If
the cDNA libraries each had possessed 1 million or more microRNA reads to increase
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statistical power, more significantly differentially expressed serum microRNAs may have
been revealed.
Tissue
Six microRNAs were found to be differentially expressed in BE pathogenesis (Table 6).
Of these six, only two microRNAs, miR-596 and miR-4655-3p, were novel. In previous
studies, over 90 microRNAs have been found to be differentially expressed in BE and
EAC tissues [94]. While not all 90 microRNAs passed the Bonferroni threshold and thus
were not considered statistically significant, many serum and tissues still appeared to be
differentially regulated in this study in the same manner as in literature (Table 11). In this
study, only three of the 90 microRNAs appeared as significantly differentially expressed
in the fresh-frozen patient tissues (Table 11). This may be due to small sample size; only
5-8 patients were available for each pathology group. This small sample number perhaps
could not overcome the variability within the pathology groups caused by the
heterogeneity inherent to BE and its associated dysplasia and EAC.
To identify differential expression of microRNAs in BE pathogenesis, previous studies
have employed targeted experimental techniques such as microarrays and qPCR [94].
Prior to this study, next generation sequencing techniques, which capture global
microRNA expression, had been utilized in three studies for BE pathogenesis [217-219].
Expression fold changes for tissue microRNAs identified in these studies generally match
the direction of differential expression observed in this study for comparisons between
BE and GERD and EAC and GERD.
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Table 11: Serum and Tissue microRNAs Differentially Expressed in BE Literature
Serum
Tissue
1
3
microRNA
Adjusted p-value Fold Change Adjusted p-value3 Fold Change
2,4
miR-196a-5p
2.58E-04
1.87
2.70E-07
18.31
miR-3613-5p2
4.99E-03
1.49
1.83E-03
1.21
miR-375
----3.03E-03
1.03
miR-135b-3p
----1.85E-03
1.33
miR-192-5p
----2.85E-04
2.06
miR-194-5p4
----1.39E-04
2.67
4
miR-196b-5p
----1.77E-06
23.19
miR-199a-5p
----2.91E-03
1.04
4
miR-215-3p
----2.13E-04
37.88
miR-542-3p
----1.25E-03
2.04
miR-136-3p
2.41E-03
1.43
----miR-29c-3p
4.55E-03
1.08
----miR-30a-3p
2.01E-03
2.04
----miR-376c-3p
2.34E-03
1.41
----miR-409-3p
7.24E-05
3.39
----miR-501-5p
8.62E-04
1.69
----miR-551b-3p
2.12E-03
1.17
----2
miR-133a-3p
1.39E-03
-1.09
1.85E-03
-1.35
2
miR-33a-3p
3.37E-03
-1.18
1.18E-03
-1.64
2
miR-99a-3p
2.50E-03
-1.43
5.96E-04
-2.31
miR-543
----3.09E-03
-1.43
miR-4462
----5.83E-04
-1.65
miR-125b-2-3p
----3.39E-03
-1.65
miR-127-3p
----1.73E-03
-1.37
miR-133b
----2.38E-03
-1.03
miR-136-5p
----7.77E-04
-1.73
miR-149-5p
----2.29E-04
-3.93
miR-154-5p
----8.39E-04
-2.02
miR-205-5p
----6.14E-05
-12.27
miR-224-5p
----1.23E-03
-3.60
miR-382-5p
----1.89E-03
-1.66
miR-708-5p
----6.39E-04
-2.53
miR-10a-5p
2.71E-04
-2.26
----miR-1-3p
1.82E-04
-3.35
----miR-18a-3p
3.56E-03
-1.02
----1
Show similar trends in expression levels in BE literature and in BE vs GERD
comparison from small RNA-seq
2
Differentially Expressed in both Serum and Tissue data sets from small RNA-seq
3
p-values Bonferroni-corrected for multiple comparisons.
4
Determined to be significantly differentially expressed after Bonferroni correction
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As previously discussed, BE pathogenesis is continuous, rather than consisting of discrete
stages. Perhaps if 1 million or more microRNA reads for each library had been obtained
or if more samples per pathology group had been collected, the biological limitations to
this study could have been surmounted.
HOX microRNAs may regulate posterior HOX genes as part of a Negative
Feedback Mechanism
Two of the candidate tissue microRNAs from this study, miR-196a-5p and miR-196b-5p,
are considered HOX microRNAs, as they are transcribed from genes intergenic to HOX
genes [220]. HOX genes are homeotic genes, a set of transcription factors that contain a
DNA-binding homeobox domain. These genes are responsible for gene expression
patterning along the AP axis and as such are essential for establishing and maintaining
the identities of the foregut, midgut, and hindgut in embryonic development [74]. In the
human, thirty-nine HOX genes are divided into four gene clusters, the results of past
genome duplications [80]. In the A, B, C, and D clusters, the HOX genes are organized
on the chromosome in order of their expression on the AP axis (Figure 16). Correct HOX
gene function is dependent on the place and time of its expression. Generally, the HOX
genes are grouped into three groups: anterior, central, and posterior (Figure 16) [71, 72].
Central HOX genes from the HOXB cluster have been found to be upregulated in BE
tissues [69]. No studies to date have examined the differential expression of microRNAs
and their regulation of HOX genes in BE pathogenesis.
Five HOX microRNAs can be transcribed from within the human HOX clusters [220].
miR-10a-5p, miR-10b-5p, and miR-615-3p can be transcribed from genes intergenic to
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Figure 16: Collinear Expression of HOX genes on the Anterior/Posterior (AP) Axis
Four HOX gene clusters in humans are a result of multiple genome duplications. Thirtynine HOX genes are divided across these clusters. Not all HOX clusters contain all 13
gene homologs. Genes are grouped into three general categories: anterior (HOX1-3),
central (HOX4-8), and posterior (HOX 9-13). These categories define the positional
expression for those HOX genes. Arrows denote locations of genes encoding HOX
microRNAs: (A) MIR-196b encodes miR-196b-5p. (B) MIR-196a-1 encodes miR-196a5p. (C) MIR-196a-2 encodes miR-196a-5p (D) MIR-10a encodes miR-10a-5p (E) MIR10b encodes miR-10b-5p (F) MIR-615 encodes miR-615-3p.
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anterior HOXA, HOXD, and HOXC genes, respectively (Figure 16) [220]. In this study,
these three microRNAs all displayed increased expression in the BE vs GERD
comparison for the tissue dataset. However, the differential expression did not pass the
Bonferroni threshold and therefore was not considered statistically significant. miR-10a5p and miR-10b-5p are among the twenty most important microRNAs in the tissue
randomForest classification analysis (Figure 10). miR-10a-5p and miR-615-3p are among
the twenty most important microRNAs in the tissue randomForest regression analysis
(Figure 11).
miR-196a-5p can be transcribed from genes intergenic to either posterior HOXB or
HOXC genes, while miR-196b-5p originates from a gene adjacent to HOXA9 [220].
HOX microRNAs are often co-expressed with adjacent HOX genes. Both microRNAs
had significantly increased expression in BE tissues when compared to GERD tissues in
this study. In Huntington’s Disease, miR-196a-5p upregulation has been correlated with
increased transcription of HOXC10 or HOXB9, while upregulation of HOXA10,
HOXA11, or HOXA13 have been associated with increased expression of miR-196b-5p
[186]. In this study, the comparative upregulation of these two microRNAs in the BE
patients may indicate an initial increase in central and posterior HOX gene expression in
BE development (Figure 17).
Gene target analysis for miR-196a-5p and miR-196b-5p demonstrated regulation of
central and posterior HOX genes from the HOXA, HOXB, and HOXC clusters (Table
10). This may be evidence of a negative feedback mechanism where posterior HOX
genes are targeted by co-expressed HOX microRNAs (Figure 17).
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Figure 17: A Model for Homeotic Gene Regulation in BE Development
In BE development, increased expression of miR-196a-5p, miR-196b-5p, and miR-2153p may indicate a mechanism for fine tuning posterior HOX gene expression in the distal
esophagus. miR-196a-5p and miR-196b-5p can both be transcribed from genes adjacent
to posterior HOX genes. miR-196b-5p and miR-196a-5p are transcribed from genes
intergenic to the HOXA and HOXB and HOXC clusters. Their co-expression with
posterior HOX genes allows for their targeting of central and posterior genes in the other
HOX gene clusters, a negative feedback mechanism. miR-196b-5p is also known to
target MEIS1, a HOX co-factor. MLL complex activates HOX genes by methylation of
histone 3 at Lysine 4 (H3K4me) and opening chromatin structure. MLL complex can also
methylate histone3 at Lysine 79 (H3K79me) at MIR-196b in the HOXA cluster, leading
to miR-196b-5p expression. CDX1 can bind to HOX gene promoters to activate HOX
gene expression. CDX1 also activates miR-215-3p, allowing this microRNA to target
BMI1, a component of PRC1. PRC1 and PRC2 work in conjunction to trimethylate
histone 3 at Lysine 27 (H3K27me3) and compact chromatin structure. Thus, posterior
HOX genes may be aberrantly expressed in BE pathogenesis under indirect and direct
regulation by the candidate microRNAs of this study.
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miR-215-3p and miR-196b-5p are involved in indirect regulation of HOX gene
expression
In humans, polycomb repressive complexes (PRC) and complexes of Mixed Lineage
Leukemia (MLL) proteins work in opposition to regulate HOX gene expression [81, 84].
PRC2 and PRC1 act in conjunction to repress HOX gene expression through methylation
of histone H3 at Lysine 27 (H3K27me) and compaction of chromatin structure,
respectively [221]. Transcription machinery access to HOX genes located in PRC1catalyzed compacted chromatin would be restricted [222]. Thus, PRC1 can repress
central or posterior HOX gene expression in anterior regions of the body. MLL is a
histone methyltransferase that binds to promoters of HOX genes and methylates histone
H3 at Lysine 4 (H3K4me) to activate HOX gene expression [81]. The H3K4me
epigenetic mark can recruit chromatin remodeling factors which open chromatin and
allow active transcription [223].
miR-215-3p targets BMI1, a component of PRC1
PRC2 trimethylates histone H3 at Lysine 27, a signal which recruits PRC1 through one of
its core components, BMI1 [224]. The exact mechanism behind PRC1’s ability to
compact chromatin is still unclear. BMI1 is required for PRC1-catalyzed chromatin
compaction and subsequent gene silencing [225]. BMI1 is an experimentally-validated
target of miR-215-3p [189]. Expression of posterior HOXB genes in BE tissues was
associated with loss of the H3K27 methylation and decompaction of chromatin at the 5’
end of the HOXB gene cluster [69]. This would suggest that PCR1 repression of central
and posterior HOXB genes in the distal esophagus is released in BE development.
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CDX1 has been shown to promote expression of miR-215-3p (Figure 17) [189]. CDX
genes, including CDX1, are known regulators of HOX genes [39]. CDX gene mutations
in humans can lead to homeotic transformations in the central regions of the body due to
dysregulation of posterior HOX genes [47]. CDX binding sites have been found in
enhancer elements of HOX genes, where CDX genes are thought to acetylate H3K27 to
activate central HOX genes [93]. CDX1 expression in the distal esophagus may precede
central and posterior HOX gene expression in BE.
Multiple Lineage Leukemia (MLL) Complex promotes mir-196b-5p expression
MLL1 is a human homolog to Trithorax originally identified in Drosophila [226]. In
embryonic development, MLL1 works in a complex with other MLL proteins to
upregulate central and posterior HOX genes in the posterior segments of the body [82].
MLL complexes directly bind to HOX promoters to apply an activating epigenetic
marker, H3K4 trimethylation [81] [84, 227, 228]. The presence of H3K4me3 recruits the
transcription factor TFIID, an initiating player in gene transcription [228-230]. No study
to date has examined differential expression of MLL in the human esophagus.
MLL complex has been shown to promote miR-196b-5p expression [231]. This complex
methylates Lysine 79 on histone H3 (H3K79me) in certain regions of the HOXA cluster
[231]. This epigenetic modification is associated with transcription activation [232]. One
region that is affected by this modification contains MIR-196b, the gene which encodes
miR-196b-5p. The observed increased expression of miR-196b-5p in the BE patient
tissues in this study may have been due to the action of MLL complex in BE
development. miR-196b-5p, in turn, can target the HOX cofactor, myeloid ecotropic viral
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integration site 1 (MEIS1) [233, 234]. MEIS1 is a member of the three amino acid loop
extension (TALE) homeobox gene cluster, which all encode atypical homeodomains
[235]. These genes act as cofactors for HOX genes by augmenting their DNA binding,
thereby enhancing transcriptional regulation by HOX genes [236]. Thus, increased
expression of miR-196b-5p has a detrimental effect on the activity of HOX genes.
A Model for Homeotic Gene Regulation in BE Development
It is unknown what molecular mechanisms contribute to the formation of BE lesions in
GERD patients. Three candidate microRNAs were identified by small RNA-seq in freshfrozen BE patient tissues and validated in FFPE BE tissues by qPCR. Upregulation of
miR-196a-5p, miR-196b-5p, and miR-215-3p posits a model for direct and indirect
regulation of central and posterior HOX genes in BE development (Figure 17).
The upregulation of miR-196a-5p and miR-196b-5p in BE tissues indicates that posterior
HOX genes are expressed in BE development, as these HOX microRNAs can be coexpressed with their adjacent HOX genes. Posterior HOX genes may exist in a bivalent
state in the distal esophagus. Bivalency describes the presence of active (H3K4me) and
repressive (H3K27me) epigenetic markers in the same gene promoter [237, 238]. This
allows affected genes to be silenced but be “poised” for activation. The actions of the
PRC1/2 complexes and the MLL complex may be in balance to keep posterior HOX
genes in a bivalent state. The onset of BE development, increased expression of miR215-3p and other factors may upset this balance. Removal of PRC1 repression of
posterior HOX genes could be achieved by the observed upregulation of miR-215-3p in
BE tissues, as this microRNA targets BMI1, a component of PRC1. miR-215-3p is
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upregulated by CDX1, a well-known biomarker of BE lesions and regulator of central
and posterior HOX genes[39, 93, 189]. This would allow for co-expression of miR-196a5p, miR-196b-5p and their respective adjacent HOX genes. MLL complex can promote
expression of miR-196b-5p as well [231, 233]. miR-196a-5p and miR-196b-5p are then
able to target central and posterior HOX gene expression and activity [220, 233].
Increased expression of miR-196a-5p, miR-196b-5p, and miR-215-3p in BE development
may allow for fine-tuning of central and posterior HOX gene expression in the distal
esophageal epithelium (Figure 17). To test this model, modulation of HOX gene and
microRNA expression in an experimental construct of BE development would need to be
assessed. Unfortunately, a technical limitation that has impeded the understanding of BE
pathogenesis is the lack of an adequate experimental model of BE. Human esophagus is
lined with a non-keratinized squamous epithelium with submucosal glands. Mice and
rats, commonly utilized model organisms, have keratinized-lined esophagi which lack
submucosal glands [239]. It is known that BE can occur in the ducts of the esophageal
submucosal glands, termed ductal metaplasia or buried BE [240]. This ductal metaplasia,
like BE, is capable of dysplasia and can produce EAC [241]. The position of the
gastroesophageal junction is also of import in BE development, as BE is confined to the
distal esophagus. In mice, induced BE-like lesions can occur in the esophagus and
proximal stomach, because this junction is positioned further down the GI tract[239].
However, the most important factor which separates humans from commonly used
animal models is that gastroesophageal reflux is a natural occurrence. In other nonprimate mammals, including mice, dogs, and pigs, reflux must be surgically induced in
order for BE-like lesions to develop [239]. Due to the lack of a practical and biologically
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relevant animal model, cell lines can be utilized to explore BE development in vitro.
However, since BE is a metaplasia consisting of both columnar epithelia and intestinaltype cells, molecular signaling in a single esophageal cell line does not necessarily reflect
the molecular signaling in the tissue. One technique to address the limitations of a single
2-D cell line has been a co-culture of multiple esophageal epithelial cell lines in a
collagen matrix [242]. Though this 3-D culture system better approximates the BE
physiology, it did not include the intestinal-type cells characteristic of BE. There is a
distinct need for a model system derived from human esophageal tissue which can be
cultured and maintained long-term, while still reflecting all the hallmarks of the BE
phenotype.
If an appropriate experimental construct of BE development can be identified,
modulation of central and posterior HOX gene transcription and translation would need
to be explored. While qPCR is a standard assay technique for gene transcription, an array
of techniques could be utilized to assay for HOX protein expression. In their 2012 study,
Di Pietro et al utilized in situ hybridization and western blots to probe for HOX gene
expression in BE tissues [69]. To further verify that the three candidate microRNAs
target central and posterior HOX genes, BMI1, and MEIS1, a biotin-based pull-down
assay may be utilized [243]. This method has been shown to be more specific than other
techniques to validate microRNA targets, such as microRNA overexpression experiments
[244]. microRNAs can block association of an mRNA with ribosomes to block
translation, thus polyribosome (polysome) fractionation analysis can determine the
strength of microRNA targeting [245, 246].
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The model presented in Figure 17 is only possible through modulation of chromatin
structure enacted through histone modifications by PRC1 and MLL complexes.
Chromatin Immunoprecipitation (ChIP) can be utilized to assess methylation and
acetylation at Lysines 27 and 79 on histone H3 at HOX gene promoters [247]. This
technique could also validate binding of MLL1 and CDX1 to intergenic regions of central
and posterior HOX genes.
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Appendix I: small RNA sequencing of Serum and Tissue cDNA libraries
Ion PI Number Concentration
Percent
Chip
of
of Pooled
Templated
Number Samples
Libraries
ISPs1

Total
Reads
Per Chip

Percent
Adaptor
Dimer

Percent
MultiTemplated
ISPs1

12

9

5pM

11%

26,165,642

58%

24%

2

8

5pM

11%

33,467,142

61%

14%

3

13

5pM

10%

24,327,612

76%

16%

4

13

7.5pM

10%

24,983,549

78%

12%

53

4

5pM

29%

17,460,404

16%

28%

6

5

5pM

8%

23,737,059

71%

26%

7

5

5pM

8%

12,794,097

70%

24%

8

5

15pM

13%

25,780,881

74%

16%

9

7

15pM

19%

42,018,947

62%

17%

10

7

15pM

15%

28,952,314

77%

12%

11

6

20pM

32%

35,833,666

65%

20%

12

9

15pM

21%

36,567,578

66%

21%

13

6

15pM

28%

46,417,922

53%

25%

14

10

15pM

19%

38,863,719

48%

24%

15

9

15pM

28%

43,534,071

61%

16%

16

14

15pM

23%

45,600,035

55%

25%

1

ISP: Ion SphereTM Particles
2
Inefficient loading of the Ion PI chip affected total and microRNA reads. Samples
were rerun on Chip 2
3
Inefficient loading of the Ion PI chip affected total reads but not microRNA reads.
Small RNA control from kit was included.

133

Appendix II: cDNA libraries from Serum and Tissue small RNAs
Patient
Sample3

Pathology
Group

1S
1T
2S
2T
3S
3S
3S
3T
3T
4S
4T
4T
5S
5S

BE
BE
GERD
GERD
GERD
GERD
GERD
GERD
GERD
Normal
Normal
Normal
GERD
GERD

5T

GERD

6S
6S
6T
7S
7T

GERD
GERD
GERD
GERD
GERD

8S

GERD

8T

GERD

9S
9S
9T
9T

Normal
Normal
Normal
Normal

10S

GERD

10T

GERD

11S
11S
11T

BE
BE
BE

50-300bp

94-114bp

cDNA
(nmol/ul)

cDNA
(nmol/ul)

Barcode

reads2,3

reads2,3

reads2,3

148.6
82.8
123.2
115.2
34.8
95
81.8
205.2
178.15
365.5
46.9
160.4
95.7
160.1
No library
made
257.9
117.6
87.5
425.30
41.3
Not
received
Not
received
205.2
283.6
109
20.5
Not
received
Not
received
259.35
315
166.8

28
51
49.2
66.8
10
18.05
26.5
71
72.45
2.36
22.7
94.9
11.1
23.9

2
7
3
14
1
1
1
9
8
7
1
1
11
12

1,165,368
409,317
493,212
587,689
----857,667
--65,358
2,058,239
--820,424
-----

-----------------------------

-----------------------------

---

---

---

---

---

186.9
70.6
59.3
275.1
29.9

8
14
2
9
3

67,564
39,076
1,538,959
3,939,615
67,000

65,239
24,837
675,776
--50,000

45,648
--619,922
-----

---

---

---

---

---

---

---

---

---

---

131.35
62.3
76.2
18.8

15
10
4
4

52,955
259,675
403,891
478,133

20,425
-------

20,294
-------

---

---

---

---

---

---

---

---

---

---

158.25
173
59.7

16
10
6

--24,928
89,451

-------

-------

microRNA microRNA microRNA
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12S
12S
12T
13S
13T
13T
13T
14S

LGD
LGD
LGD
EAC
EAC
EAC
EAC
GERD

14T

GERD

15S
15T
15T
15T
16S1
16T
16T1
16T
17S
17S1
17S
17T
17T
18S
18S
18S
18T
18T
19S1
19S
19S
19T
19T
20S
20S
20S
20T
20T
21S1
21S
21S

BE
BE
BE
BE
LGD
LGD
LGD
LGD
LGD
LGD
LGD
LGD
LGD
BE
BE
BE
BE
BE
GERD
GERD
GERD
GERD
GERD
BE
BE
BE
BE
BE
GERD
GERD
GERD

122.9
40.3
99.1
334.2
135.2
214.9
241.1
10.3
Not
received
227.5
24.2
63.5
247.6
87.8
128.85
28
15.2
71.3
368.8
165
41.2
331.9
48.1
338.1
244
120.05
120.05
67.1
374.3
447
74.75
257.4
57.9
587.2
79.4
166.7
187.7
489.2
366.8
371.6

0.7
18.6
71.7
226.6
98.85
150.4
153
2.05

9
15
12
11
5
5
1
13

--47,583
157,235
267,217
84,000
336,937
733,000
---

------162,316
40,000
-------

------77,946
31,000
-------

---

---

---

---

---

130.7
9.1
42.3
174.6
33.7
70.1
12
11.1
19.2
151.7
110.8
28.15
215.7
27.8
162
183.6
91.35
91.35
15.9
196.3
258.1
60.45
194.9
24.5
236.1
56.1
129.1
131.8
84.6
177.9
225.7

12
6
6
4
13
7
5
7
1
1
1
7
2
2
2
2
8
8
3
3
3
9
6
4
4
4
10
10
5
5
5

565,053
--130,000
454,000
225,876
373,289
171,798
269,103
--261,515
----1,494,000
--844,152
119,000
37,997
121,174
195,120
299,691
123,113
155,621
----1,620,830
100,000
2,009,572
63,046
64,190
2,917,007

367,094
--105,000
--110,003
303,889
--------------------76,000
--------120,310
------617,535
90,000
---------

65,239
------------------------------62,000
--------79,137
------540,092
79,000
---------
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21T1
21T
21T
22S
22S
22S
22S
22T
23S
23T
24S
24T
24T
25S
25S
25T
26S
26T
26T
27S
27T
27T
27T
24T
24T
25S
25S
25T
26S
26T
26T
27S
27T
27T
27T
28S
28S
28T
28T
29S
29S

GERD
GERD
GERD
BE
BE
BE
BE
BE
GERD
GERD
BE
BE
BE
Normal
Normal
Normal
EAC
EAC
EAC
EAC
EAC
EAC
EAC
BE
BE
Normal
Normal
Normal
EAC
EAC
EAC
EAC
EAC
EAC
EAC
LGD
LGD
LGD
LGD
BE
BE

92.4
199.9
9.6
53
376.7
143.6
315.3
129.8
211.2
79.05
219.4
64.55
230.5
56.8
304.2
123.4
274.9
173
215.3
370
54
28.05
238.7
64.55
230.5
56.8
304.2
123.4
274.9
173
215.3
370
54
28.05
238.7
242.45
131.4
80.1
272.1
90.35
455.8

57.9
157.1
9
12.6
153.6
52.7
91.4
92.2
117.2
51.95
130.1
41.15
174.7
37.5
199.3
73.6
148.1
132.4
148.9
276.4
32.5
17.5
172.7
41.15
174.7
37.5
199.3
73.6
148.1
132.4
148.9
276.4
32.5
17.5
172.7
86.25
102.5
60.2
171.1
46
309.5

11
7
11
6
6
6
6
12
13
13
14
14
8
15
15
15
16
16
10
10
1
13
3
14
8
15
15
15
16
16
10
10
1
13
3
2
2
2
9
3
3
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77,965
403,686
103,850
------105,306
60,866
1,731,449
240,323
660,978
135,218
156,000
2,056,656
65,373
121,540
221,207
130,000
2,762,128
201,209
----575,000
135,218
156,000
2,056,656
65,373
121,540
221,207
130,000
2,762,128
201,209
----575,000
--217,622
--1,664,468
--836,870

------------------226,658
460,448
------------98,000
--115,318
------------------98,000
--115,318
--------130,048
------473,280

------------------172,304
------------------61,062
----------------------61,062
--------73,585
---------

29T
29T
30S
30S
30T

BE
BE
Normal
Normal
Normal

31S

ESCC

31T
32S
32S
32T
32T
33S
33T
34S
34T
34T
35S
35T
36S
36T
36T
37S
37T
37T
37T
38S
38S1
38T
38T
38T
39S
39S
39T
40S1
40T

ESCC
GERD
GERD
GERD
GERD
BE
BE
EAC
EAC
EAC
GERD
GERD
GERD
GERD
GERD
LGD
LGD
LGD
LGD
EAC
EAC
EAC
EAC
EAC
LGD
LGD
LGD
Normal
Normal

118.1
37.95
129.8
77.3
106.3
Library not
made
64.3
231.6
136.9
20.6
93.1
119.2
120.3
461.55
78.05
409.7
374
350.8
404.3
301.8
324.7
494.00
82.45
82.45
195
294.8
229.8
65.1
65.1
158.9
361.88
57.7
64.6
108.4
34.1

83.7
24.95
65.7
31.2
69.4

3
15
4
16
4

116, 949
236,985
--754,897
1,031,683

---

---

---

43.5
158.8
64.2
8.1
49.7
57.2
77.5
229.05
42.6
283.8
243.7
259.1
235
205
230.6
290.45
46.25
46.25
109
116.85
105.75
45.45
45.45
85.4
176.4
41.6
45
59.5
17.5

5
14
4
9
16
5
11
8
8
4
2
8
7
14
1
11
11
11
5
12
12
12
12
12
13
13
13
6
5

----602,971
--1,115,086
910,976
460,777
247,384
79,052
652,918
109,889
--1,670,527
101,000
330,521
5,969,490
98,000
48,000
4,060,390
--578,011
23,310
16,829
2,705,433
1,651,601
--769,308
13,538,600
2,620,041

1

-------------

-------------

----------------------------------------58,714
-----------------

-----------------------------------------------------------

Library was suboptimal (contained adaptor dimers and/or t-RNA peaks)
MicroRNA reads were provided by Ion Torrent smallRNA_analysis plugin, a quality control step.
Read counts herein differ from those reported in Table 5 as the Ion Torrent and Partek Flow®
map raw reads to different versions of miRBase, v20 and v21, respectively.
3
Libraries in bold-type had over 200,000 microRNAs and were included in further analyses
2
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Appendix III: Variance of TMM-normalized microRNA reads of Selected microRNAs
microRNA1

Normal

GERD

BE

LGD

EAC

hsa-miR-106b-5p

1.60E+08

4.58E+07

1.04E+07

1.52E+08

6.01E+05

hsa-miR-15a-5p

4.15E+08

1.91E+08

3.19E+07

1.30E+08

4.79E+06

hsa-miR-181a-5p

2.07E+07

2.40E+06

1.00E+07

1.05E+07

5.82E+06

hsa-miR-194-5p

6.01E+04

1.96E+04

4.65E+03

1.31E+04

1.80E+02

hsa-miR-6131

2.17E+06

2.68E+05

4.41E+06

3.53E+05

7.22E+04

hsa-miR-92a-3p

7.81E+07

4.36E+07

3.37E+07

3.03E+07

1.21E+06

hsa-miR-93-5p

3.14E+08

7.50E+06

7.57E+06

6.56E+07

2.10E+06

hsa-miR-106b-5p

1.75E+06

3.52E+04

3.02E+05

5.15E+05

1.29E+07

hsa-miR-15a-5p

2.85E+06

1.56E+05

1.57E+05

8.28E+05

2.63E+07

hsa-miR-181a-5p

1.67E+05

5.56E+03

6.47E+04

1.60E+05

1.32E+05

hsa-miR-194-5p

1.87E+02

1.61E+05

2.53E+05

1.84E+06

4.74E+06

hsa-miR-6131

4.83E+02

9.79E+02

1.76E+03

1.01E+04

2.31E+04

hsa-miR-92a-3p

2.97E+05

2.73E+03

2.91E+03

4.20E+04

8.76E+05

hsa-miR-93-5p

3.09E+06

7.44E+04

1.45E+04

2.03E+05

4.93E+06

Serum2

Tissue2

1

Selected microRNAs were chosen based on a GSA performed on serum or tissue
datasets composed of the same 24 patients (unshown). These microRNAs were unique to
a specific pair-wise comparison between two of the five patient groups.
2

TMM-normalized microRNA reads from those 24 patients for which both serum and
tissue samples passed the 200,000 microRNA read count threshold
3

Instances when variance in the Normal patient group exceeded variance in other patient
groups are in boldtype
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